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strong risk factor for an increase in immediate postoperative1. Preamble
Cardiac surgery is associated with perioperative blood loss
and a high risk of allogeneic blood transfusion. Patient blood
management (PBM) in cardiac surgery contributes to the
maintenance of perioperative haemostasis and the minimiza-
tion of bleeding, which reduce blood transfusion requirements.
PBM in cardiac surgery comprises an interaction between the
cardiothoracic surgeon, the anaesthesiologist and the clinical
perfusionist. The impact of cardiopulmonary bypass distin-
guishes this discipline from other surgical specialities.
In a joint effort, the European Association for Cardio-Thoracic
Surgery (EACTS) and the European Association of Cardiothor-
acic Anaesthesiology (EACTA) provide evidence-based recom-
mendations for PBM in adult-acquired cardiac surgery. Literature
searches were based on the Population, Intervention, Comparison,
Outcome and Time (PICOT) method using standardized Medical
Subject Headings (MeSH) terms from the National Library of
Medicine, PubMed and Embase database lists of search terms.
The PICOT study end points included bleeding, transfusions and
reoperations for bleeding. The guideline was reviewed by an
external review method and endorsed by the EACTS and the
EACTA in collaboration with the editors of the European
Journal of Cardio-Thoracic Surgery and the Journal of Cardi-
othoracic and Vascular Anesthesia.
This guideline provides practical recommendations for all
clinicians working in the ﬁeld of PBM in cardiac surgery,
with emphasis on preoperative patient optimization and risk
reduction, intraoperative maintenance of haemostasis and
postoperative treatment for bleeding complications.2. Introduction
Cardiac surgery is known to be associated with a high risk
of perioperative blood loss and allogeneic blood transfusions
due to the invasiveness of the procedures, the need for high-
dose anticoagulation and the exposure to cardiopulmonary
bypass (CPB). Both high blood product transfusion require-
ments and reoperation for bleeding have been associated with
adverse clinical outcomes.1,2 The implementation of a multi-
disciplinary patient blood management (PBM) programme, the
goal of which is meticulous surgical and perioperative
haemostasis and minimization of blood loss, may, therefore,
contribute to a reduction in transfusion requirements, a
decrease in health care costs and an improvement in patient
outcomes.Even the transfusion of 1 or 2 units of packed red blood cells
(PRBCs) has been associated with a dramatic increase in morbidity,
mortality and costs in patients undergoing coronary artery bypass
grafting (CABG).3 However, it remains unclear whether these
complications are independent predictors of outcome or more
surrogate markers of surgical complexity and complications. In
mortality and morbidity. There is, however, no general consensus
on when exploration for postoperative bleeding is indicated, and
surgical practice varies considerably in this regard.4 The ﬁrst step
towards creating algorithms to decrease blood loss and transfusions
is to identify patients at high risk of bleeding, transfusion
requirements and reoperation for bleeding. Also, there is little
consensus on what constitutes a massive blood transfusion and
what thresholds might be associated with adverse outcomes.5,6
Several factors have been found to be associated with an
increased risk of bleeding, transfusion and reoperation,7–9
including advanced age, preoperative dual antiplatelet therapy
(DAPT) use, poor platelet function, preoperative anaemia,
small body surface area, the female gender, non-elective
surgery, nonisolated surgery, non-CABG surgery and redo
surgery. In an attempt to facilitate the preoperative prediction
of the need for transfusion, several scoring methods have been
developed.7,10–15 However, most of these risk models are of
uncertain relevance, because they have not been externally
validated. Risk prediction algorithms are, therefore, mostly used
to stratify outcomes and allow risk-adjusted benchmarking in
the context of quality and outcome monitoring.
PBM in cardiac surgery comprises an interaction between
the surgeon, the anaesthesiologist and the clinical perfusionist,
and the use of CPB distinguishes this discipline from other
surgical specialities. Despite the availability of recent guide-
lines on PBM,9,16,17 there are currently no PBM guidelines
available that speciﬁcally address the unique context of cardiac
surgery and that are endorsed by the European societies. In a
joint effort, the European Association for Cardio-Thoracic
Surgery (EACTS) and the European Association of Cardio-
thoracic Anaesthesiology (EACTA) collaborated on a common
guideline with evidence-based recommendations for PBM in
adult-acquired cardiac surgery conditions.3. Methods
As an expression of their declared and consolidated interest
in medical care and scientiﬁc research in the ﬁeld of PBM in
cardiac surgery, the EACTS Council and the Board of
Directors of EACTA selected a task force of experts, including
a clinical methodologist. After the scope of the clinical
guideline had been agreed upon by the task force members,
a preliminary review of previous guidelines was performed.
The scope and table of contents were established by co-chairs,
and topics were allocated to the writing group. A systematic
review of the published evidence in the ﬁeld of blood
conservation during adult-acquired cardiac surgery was
Table 2
Levels of evidence
Level of evidence A Data derived from multiple randomized clinical
trials or meta-analyses.
Level of evidence B Data derived from a single randomized clinical
trial or large non-randomized studies.
Level of evidence C The consensus of expert opinion and/or small
studies, retrospective studies, registries.
Levels of evidence based on the Methodology Manual for European Associa-
tion for Cardio-Thoracic Surgery clinical guidelines.18
Recommendations Classa Levelb Refc
Preoperative ﬁbrinogen levels may be
considered to identify patients at high
risk of bleeding.
IIb C
Routine use of viscoelastic and platelet
function testing is not recommended to
predict bleeding in patients without
antithrombotic treatment.
III C
Platelet function testing may be
considered to guide the decision on the
timing of cardiac surgery in patients
who have recently received P2Y12
inhibitors or who have ongoing DAPT.
IIb B 20–22
aClass of recommendation.
bLevel of evidence.
cReferences.
DAPT: dual antiplatelet therapy.
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Outcome and Time (PICOT) questions. Task force members
undertook an evidence review; they were assisted by 2 research
fellows with an MD/PhD in anaesthesiology and an MSc in
clinical epidemiology, respectively. After study selection and
quality assessment, tables of recommendations were drafted
based on the synthesis of the best medical evidence. The
experts conducted a review of the available evidence and
followed the Methodology Manual for EACTS clinical guide-
lines.18 All chapters were written through a collaboration
between an EACTS member and an EACTA member. Agree-
ment was reached through conference calls and face-to-face
meetings, without excluding members with a conﬂict of
interest. When no agreement could be obtained, a consensus
was reached following a modiﬁed Delphi process.19 Task force
members who were unable to attend a face-to-face meeting
voted by email. Three Delphi rounds were required to reach a
consensus, and a ﬁnal decision was made through a series of
teleconference calls. Chapters were written by task force
members who did not have a disclosure for the speciﬁc topic.
The literature was restricted to the years 2001–2017 to focus
on contemporary evidence. The guideline only focused on
adult-acquired cardiac surgery and did not include studies in
the areas of transplantation, trauma, circulatory arrest or long-
term circulatory support. Outcomes were deﬁned as bleeding
volume or chest drain output in the ﬁrst 24 h following surgery,
transfusion requirements and reoperation for bleeding at any
time point during hospitalization. The deﬁnitions of bleeding,
time frames of measurement and thresholds for transfusions
varied signiﬁcantly between studies. Wherever a distinction in
time frame beyond 24 h was made, it is emphasized in the text.
The medical evidence was critically appraised for quality,
including internal validity, external validity for the population of
interest and publication bias. Randomized controlled trials
(RCTs) and meta-analyses of RCTs were considered as the
highest level of evidence, followed by other study designs. When
a meta-analysis was the basis for a recommendation, the quality
was assessed by a group of specialists from the EACTS/EACTA.
In the absence of published evidence, expert consensus state-
ments were made to cover speciﬁc issues that are essential to
daily practice. The level of evidence and the strength of the
recommendations were weighed and graded according to pre-
deﬁned scales, as outlined in Table 1 and 2.Table 1
Classes of recommendations
Classes of recommendations Deﬁniti
Class I Evidence and/or general agreement that a given tr
effective.
Class II Conﬂicting evidence and/or a divergence of opinio
treatment or procedure.
Class IIa Weight of evidence/opinion is in favour of usefuln
Class IIb Usefulness/efﬁcacy is less well established by evid
Class III Evidence/general agreement that the given treatme
sometimes be harmful.
Classes of recommendations based on the Methodology Manual for European Ass4. Preoperative Management
Inadequate patient optimization before surgery increases the
risk of intraoperative anaemia and bleeding. Preoperative
measures include management of antithrombotic medication,
optimization of haemoglobin (Hb) levels in the context of
patient comorbidities and body surface dimensions and the
assessment and weighing of patient haemostatic risk factors,
including the presence of congenital disorders.
4.1. Laboratory and Point-of-Care Tests to Predict
Perioperative Bleedingon Suggested wording to use
eatment or procedure is beneﬁcial, useful and Is recommended/is indicated
n about the usefulness/efﬁcacy of the given
ess/efﬁcacy. Should be considered
ence/opinion. May be considered
nt/procedure is not useful/effective and may Is not recommended
ociation for Cardio-Thoracic Surgery clinical guidelines.18
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Preoperative assessment of haemostatic parameters by
standard laboratory testing, viscoelastic testing and/or platelet
function tests has been proposed to predict perioperative
bleeding in cardiac surgery.
Description of the Evidence
Standard Laboratory Testing. The use of routine preoperative
screening has been much debated regarding its ability to identify
high-risk patients for postoperative bleeding and transfusion
requirements. There is no association between preoperative
prothrombin time or the activated partial thromboplastin time
(aPTT) and perioperative blood loss or transfusion require-
ments.23–25 So far, the most commonly identiﬁed risk factor for
postoperative bleeding is a lowﬁbrinogen level.23,26–28 However,
despite its association with bleeding, the positive predictive value
of a low-ﬁbrinogen level remains poor (positive predictive value
o20%).26 A low-platelet count o100 x 10-9/l has been
associated with increased risk of transfusion,12 and patients with
the highest postoperative blood loss volumes show the lowest
platelet counts.24 Finally, it has been shown that patients with the
highest postoperative blood loss volumes show the lowest
thrombin generation rates,24,29 but this test is mainly used for
research purposes and is not routinely used in everyday practice.
Preoperative ﬁbrinogen levels and thrombin generation assays
may be considered to identify patients at high risk of bleeding, e.g.
during aortic or emergency surgery, although thrombin generation
assays are not yet validated for routine clinical application.
Viscoelastic Testing and Platelet Function Tests. Preopera-
tive assessment of haemostatic parameters using viscoelastic tests,
such as rotational thromboelastometry (TEM) or thromboelasto-
graphy (TEG), has been found to have a limited association with
the risk of postoperative bleeding.29–31 Preoperative platelet
function testing has not been demonstrated to be associated with
an increased risk of bleeding complications in patients without
ongoing or recently stopped DAPT. In contrast, several studies
have shown a signiﬁcant association between impaired platelet
function and bleeding complications in patients on DAPT. This
ﬁnding indicates that platelet function testing may be used to
guide the timing of surgery in this group of patients.21,22,32,33
4.2. Management of Preoperative Anticoagulant and
Antiplatelet DrugsRecommendations Classa Levelb RefcIn patients undergoing CABG, ASA
should be continued throughout
the preoperative period.IIa CIn patients at high risk of bleedingd
or refusing blood transfusions and
undergoing non-coronary cardiac
surgery, stopping ASA should be
considered at least 5 days
preoperatively.IIa CIt is recommended that ASA be
re(started) as soon as there is no
concern over bleeding (within
24 h) after isolated CABG.I B 34,35In patients taking DAPT who need
to have non-emergent cardiac
surgery, postponing surgery for at
least 3 days after discontinuation
of ticagrelor, 5 days after
clopidogrel and 7 days after
prasugrel should be considered.IIa B 36–38It is recommended that GPIIb/IIIa
inhibitors be discontinued at least
4 h before surgery.I CTo reduce the risk of bleeding,
preoperative bridging of oral
anticoagulation with UFH/LMWH
is only indicated in patients at
high risk of thrombotic events.eI B 39It is recommended that prophylactic
LMWH be discontinued 12 h
before surgery and fondaparinux
24 h before surgery. A longer
interval may be necessary for
patients with impaired renal
function and/ or therapeutic doses.I B 40–42It is recommended that OACs be
bridged with UFH.I B 43,44Bridging OACs with subcutaneous
LMWH should be considered an
alternative to bridging with UFH.IIa B 45,46Elective cardiac surgery should be
performed if the INR is o1.5 in
patients taking VKAs. When
surgery cannot be postponed,
coagulation factors should be used
to reverse the effect.IIa CIn patients having elective cardiac
surgery, DOACs should be
stopped at least 48 h before
surgery. A longer interval may be
necessary for patients with
impaired renal function.IIa CaClass of recommendation.
bLevel of evidence.
cReferences.
dComplex and redo operation, severe renal insufﬁciency, haematological
diseases and hereditary deﬁciencies in platelet function.
eMechanical prosthetic heart valve, atrial ﬁbrillation with rheumatic valvular
disease, an acute thrombotic event within the previous 4 weeks and atrial
ﬁbrillation with a CHA2DS2-VASc score 44.
ASA: acetylsalicylic acid; CABG: coronary artery bypass grafting; CHA2DS2-
VASc: congestive heart failure, hypertension, age Z75 (2 points), diabetes,
prior stroke (2 points) – vascular disease, age 65–74, sex category (female);
DAPT: dual antiplatelet therapy; DOAC: direct oral anticoagulant; GP:
glycoprotein; INR: international normalized ratio; LMWH: low-molecular-
weight heparin; OAC: oral anticoagulants; UFH: unfractionated heparin; VKA:
vitamin K antagonist.
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cornerstones for the treatment of acute and chronic cardiovas-
cular disease. Primary and secondary prevention with ASA has
been shown to reduce mortality, myocardial infarction (MI)
and stroke47 but to increase the risk of bleeding complications.
Virtually, all patients requiring CABG—independent of
whether they require emergent, urgent or elective surgery—
are treated with ASA. Figure 1 provides an overview of the
management of antiplatelet therapy in patients undergoing
CABG surgery.Description of the Evidence
Discontinuation before Surgery. A recent meta-analysis
comparing preoperative ASA administration with distinct
dosing regimens versus no treatment or placebo in patients
having CABG included 13 RCTs (n ¼ 2399 patients).48 The
meta-analysis showed that ASA reduced the risk of periopera-
tive MI [odds ratio (OR) 0.56, 95% conﬁdence interval (CI)
0.33–0.96] but not the risk of death (OR 1.16, 95% CI 0.42–
3.22). Twelve-hour blood loss, PRBC transfusions and surgi-
cal re-exploration increased with ASA. The meta-analysis was
limited by substantial heterogeneity but conﬁrmed ﬁndings
from a previous meta-analysis.49 A large RCT compared the
administration of ASA (100 mg) on the day of surgery versus
placebo in patients having CABG.50 The study showed no
effect of treatment with ASA on 24-h bleeding (mean blood
loss: 780 vs 740 ml; P ¼ 0.30) or on the incidence of death or
thrombotic complications (19.3% vs 20.4%; P ¼ 0.55).
Because patients were only eligible for inclusion if they were
not using ASA or stopped ASA 44 days before surgery,
these ﬁndings are difﬁcult to generalize to other settings.50
Another RCT demonstrated that preoperative administration of
ASA (300 mg) was associated with signiﬁcantly more patients
having post-surgical drainage losses 41000 ml (OR 1.60,Figure 1. Management of antiplatelet therapy in patients having coronary artery byp
haematological diseases and hereditary deﬁciencies in platelet function. bRecent sten
cUntil the recommended DAPT period is completed. ASA: acetylsalicylic acid; DA95% CI 1.17–2.18) but with a lower rate of major cardiovas-
cular events at the 53-month follow-up compared with placebo
[hazard ratio (HR) 0.65, 95% CI 0.41–1.03].51 In a small RCT
in patients with a platelet glycoprotein (GP) IIIa polymorph-
ism, treatment with ASA (300 mg) increased the risk of
postoperative bleeding (þ25%).52
If one considers all of the results from the different studies,
continuation of ASA is associated with more blood loss but
also reduces ischaemic events in patients having CABG. In
patients who refuse blood transfusions, who are undergoing
non-CABG surgery or who are at a high risk of re-exploration
for bleeding (e.g. in cases of complex and redo operations,
severe renal insufﬁciency, haematological disease and heredi-
tary platelet function deﬁciencies), ASA should be stopped at
least 5 days before surgery. In other patients, the prevention of
thrombotic events outweighs the risk of postoperative bleeding
events. Moreover, recent data suggest that the inhibiting effect
of ASA on platelet aggregation is reversible by platelet
transfusion,53,54 which also argues for the continuation of
ASA.
Because current evidence supports the idea that ASA should
be continued before surgery, the question of restarting applies
only to a minority of patients. In a large prospective observa-
tional trial,34 patients who restarted ASA within 48 h of
CABG had a mortality rate of 1.3% compared to 4.0% in the
group of patients who did not receive ASA during this period
(P o 0.001).
In conclusion, there is sufﬁcient evidence to recommend
continuation of ASA before cardiac surgery, and, if discon-
tinued, it should be given to all patients having CABG as soon
as there is no concern over bleeding to prevent thromboem-
bolic complications.4.2.2. Dual Antiplatelet Therapy
Background. DAPT with ASA and a P2Y12-receptor
antagonist (clopidogrel, ticagrelor and prasugrel) reduces theass grafting surgery. aComplex and redo operations, severe renal insufﬁciency,
t implantation, recent thromboembolic event and alarming angiographic results.
PT: dual antiplatelet therapy; GPIIb/IIIa: glycoprotein IIb/IIIa.
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coronary syndrome (ACS) compared with ASA treatment
only.55–57 The risk of thrombotic complications is further
reduced if a second-generation P2Y12 antagonist (ticagrelor/
prasugrel) is used instead of clopidogrel,56,57 but the risk of
both spontaneous and surgical bleeding complications
increases with the newer antagonists.56–58 The duration of
DAPT treatment varies depending on the indication (recent
ACS and/or stent implantation, coronary endarterectomy or
off-pump surgery), bleeding risks and concomitant medica-
tions.59 Recently, cangrelor, a new reversible intravenous
P2Y12 inhibitor with an ultrashort half-life to offset the effect
after discontinuation, was introduced.60
Description of the Evidence
Discontinuation of P2Y12 Inhibitors Before Surgery. Con-
tinuation of DAPT until surgery increases the risk of post-
operative bleeding, transfusions and re-exploration for
bleeding, as shown in RCTs,36,61,62 observational studies37,63
and meta-analyses.64,65 It is therefore recommended that
P2Y12 inhibitors be discontinued before elective surgery
whenever feasible.66,67 Of note is the fact that, if P2Y12re-
ceptor inhibitors are discontinued, ASA therapy should be
continued until surgery. Alternatively, elective non-cardiac
and cardiac procedures may be postponed until the DAPT
treatment period is completed. In urgent cases, the risk of
thromboembolic episodes must be weighed against the risk of
perioperative bleeding complications. In extremely high-risk
patients (e.g. patients with recent stent implantation),
bridging therapy with cangrelor or a GPIIb/IIIa blocker
may be considered.66,67
The safe discontinuation interval differs among distinct
P2Y12 inhibitors due to variations in the platelet inhibitory
effect and pharmacodynamic and pharmacokinetic proper-
ties.67 In the CABG substudy of the Clopidogrel in Unstable
Angina to Prevent Recurrent Events (CURE) trial, 45 days’
discontinuation of clopidogrel before surgery did not increase
the risk of bleeding [risk ratio (RR) 0.83, 95% CI 0.46–
1.48].61 For prasugrel, a time interval of 7 days is recom-
mended due to the longer offset time compared with clopido-
grel68 and the high incidence of bleeding complications
reported in the CABG substudy of the Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet
Inhibition with Prasugrel–Thrombolysis in Myocardial Infarc-
tion (TRITON-TIMI) 38 trial.36 Although it was previously
recommended that ticagrelor be discontinued at least 5 days
before surgery,69 a large observational study in CABG patients
showed that discontinuation of ticagrelor for 3 or 4 days before
surgery did not relate to a higher incidence of bleeding
complications (OR 0.93, 95% CI 0.53–1.64)37; this observa-
tion is also supported by others.38,63 Current guidelines
recommend restarting DAPT in all patients with ACS,
independent of the revascularization strategy.66,67
Because of the individual variation in the magnitude and
duration of the antiplatelet effect,21,69,70 the use of platelet
function tests may help to optimize the timing of surgery orestablish the grade of platelet inhibition in patients in whom
the time since discontinuation is unclear. The guidance is that
the interruption of therapy may be preferred over an arbitrary,
speciﬁed period.66,67 The platelet inhibitory response assessed
by platelet function testing to clopidogrel,22,32,33,71 prasu-
grel22,32,33,71 and ticagrelor21 is associated with CABG-related
bleeding. A strategy based on preoperative platelet function
testing to determine the timing of CABG in clopidogrel-
treated patients led to 50% shorter waiting times for surgical
treatment compared to those for a discontinuation time-based
strategy.20 It should, however, be pointed out that no RCT or
observational study has investigated the incidence of perio-
perative bleeding complications in relation to the time since
discontinuation-based or platelet function test-based surgery
and that deﬁned cut-off levels for acceptable platelet function
are unavailable.
Taken together, in patients taking DAPT who need to
undergo non-emergent cardiac surgery, postponement of
surgery for at least 3 days after discontinuation of ticagrelor,
5 days after clopidogrel and 7 days after prasugrel should be
considered to reduce the risk of postoperative bleeding
(Fig. 1). During discontinuation of P2Y12 inhibitors, ASA
therapy should be continued until surgery. Platelet function
testing may be used to guide the timing of surgery in patients
taking DAPT.
4.2.3. Glycoprotein IIb/IIIa Inhibitors
Background. Glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors
(eptiﬁbatide, tiroﬁban and abciximab) are today almost exclu-
sively used in conjunction with percutaneous coronary inter-
ventions but may also be used for bridging risk patients on oral
P2Y12 inhibitors to surgery.66,67,72
Description of the Evidence. The optimal time for disconti-
nuation of GPIIb/IIIa inhibitors before surgery is mainly based
on pharmacokinetic calculations. Platelet function recovery is
obtained 24–48 h after discontinuation of abciximab and 4–8 h
after discontinuation of eptiﬁbatide and tiroﬁban.73 Cessation
at 4 h before surgery is sufﬁcient for patients treated with
GPIIb/IIIa inhibitors. In a small prospective study, disconti-
nuation of eptiﬁbatide 4 h before CABG resulted in lower
bleeding rates than discontinuation 2 h before the procedure.74
For abciximab, no difference in bleeding was noted in a
pooled analysis of 82 patients in the Evaluation in Percuta-
neous Transluminal Coronary Angioplasty to Improve Long-
Term Outcome with Abciximab GP IIb/IIIa Blockade (EPI-
LOG) and Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
(EPISTENT) trials who underwent acute CABG when abcix-
imab was stopped o6 h before CABG in 61% of the
patients.75 In a small retrospective study, tiroﬁban-treated
patients having CABG showed more bleeding than patients
without tiroﬁban, but no difference was found between
different discontinuation times.76
In conclusion, GPIIb/IIIa inhibitor discontinuation at least
4 h before surgery should be considered to minimize the risk
of post-operative bleeding.
Figure 2. Management of oral anticoagulation in patients with an indication for
pre- and/or postoperative bridging (reproduced with permission from Sousa-
Uva. Stuart J. Head, Milan Milojevic, Jean-Philippe Collet, Giovanni Landoni,
Manuel Castella et al. 2017 EACTS Guidelines on Perioperative Medication in
Adult Cardiac Surgery. Eur J Cardiothorac Surg 2017; http://dx.doi.org/10.
1093/ejcts/ezx314). aBridging with UFH/LMWH should start when INR values
are below speciﬁc therapeutic ranges. bDiscontinuation should be prolonged to
472 h if creatinine clearance is 50–79 ml/min/1.73 m2 or Z96 h if creatinine
clearance is o50 ml/min/1.73 m2. DOACs: direct oral anticoagulants; INR:
international normalized ratio; LMWH: low-molecular-weight heparin; UFH:
unfractionated heparin; VKAs: vitamin K antagonists.
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Background. Low-molecular-weight heparin (LMWH; enox-
aparin and fonda-parinux) mainly inhibits activated FX (FXa),
with plasma concentration peaks 3–4 h after administration. It
is the preferred strategy for prophylactic and therapeutic
anticoagulation in patients after certain surgeries (e.g. ortho-
paedic surgery) and in patients with malignancies. The half-life
is around 5 h in patients with normal renal function. Monitor-
ing of the anticoagulant effects of LMWH can be achieved by
plasma anti-FXa activity. LMWH-induced bleeding may be
treated with protamine, but this therapy does not completely
reverse the anticoagulant effect of LMWH.
Description of the Evidence. Cardiac surgery patients receiv-
ing enoxaparin versus unfractionated heparin (UFH) more
frequently underwent re-exploration for bleeding (HR 2.6, 95%
CI 1.1–5.9).44 Patients receiving LMWH within 12 h before
surgery showed more blood loss and transfusion requirements
than patients receiving UFH or a dose of LMWH 412 h before
surgery.77 However, other studies could not conﬁrm this
ﬁnding.41 Fondaparinux versus enoxaparin before CABG
surgery resulted in the same rate of bleeding events, but when
it was not discontinued 36 h before surgery, fondaparinux was
associated with higher 12-h postoperative bleeding rates.42 The
half-life of fondaparinux is increased in patients with chronic
kidney disease.
Overall, preoperative bridging of oral anticoagulation with
UFH/LMWH is only indicated in patients at high risk of
thrombotic events. It is further recommended that prophylactic
LMWH be discontinued 12 h and fondaparinux 24 h before
surgery; a longer interval may be necessary for patients with
impaired renal function.
4.2.5. Vitamin K Antagonists
Background. Vitamin K antagonists (VKAs) are commonly
used to prevent and treat thromboembolism in patients with
atrial ﬁbrillation, venous thromboembolic disease and mechan-
ical heart valves (particularly when they are in the mitral or
tricuspid position). The anti-coagulation effect can be mon-
itored by the prothrombin time and is most often expressed as
an international normalized ratio (INR).
Description of the Evidence. VKAs are regularly stopped 3–
5 days before surgery to obtain an INR o1.5. In patients
having urgent or emergency surgery, the effect of VKA can be
completely reversed by administering prothrombin complex
concentrate (PCC). Bridging non-cardiac surgery patients who
are taking VKA with a full therapeutic dose of LMWH after
surgery is associated with increased bleeding but not with a
meaningful reduction in thrombotic events.39 Thus, bridging to
cardiac surgery is only recommended in patients at a very high
risk of thrombotic events, e.g. those with a recent (o4 weeks)
pulmonary embolism or a prosthetic mechanical valve, atrial
ﬁbrillation with the rheumatic valvular disease or atrial
ﬁbrillation with a CHA2DS2-VASc [congestive heart failure,hypertension, age Z75 (2 points), diabetes, prior stroke
(2 points) – vascular disease, age 65–74, sex category
(female)] score 44. In these patients, VKA should be
discontinued 5 days before surgery and bridged by LMWH
(Fig. 2). Bridging with UFH after surgery until the INR
reaches the therapeutic range in patients on VKAs (bridging
with subcutaneous LMWH may be considered an alternative to
bridging with UFH) is recommended. Elective cardiac surgery
should not be performed if the INR is 41.5 in patients taking
VKAs. When surgery cannot be postponed, coagulation
factors should be used to reverse the effect.
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Background. Direct oral anticoagulants (DOACs) include
direct thrombin inhibitors (dabigatran) and FXa inhibitors
(rivaroxaban, apixaban and edoxaban), and novel formulations
are under development. DOACs are increasingly used as an
alternative anticoagulation strategy for VKAs.
Description of the Evidence. Because emergency surgery in
patients under dabigatran treatment has been associated with
severe or even fatal bleeding, it is recommended that DOACs
be discontinued at least 48 h before cardiac surgery.78–80
DOACs may be bridged by heparins in patients with acute
thrombotic events o4 weeks. The half-life of DOACs may
be prolonged in case of impaired renal function (Table 3).
Whenever feasible in patients with impaired renal func-
tion, the concentration of DOAC should be measured in
terms of the diluted thrombin time (dabigatran) or calibrated
with anti-FXa activities (rivaroxaban, apixaban or edoxa-
ban). The use of viscoelastic tests is still debated in the
diagnosis of DOAC-induced prolonged clotting time. Ecarin
clotting times may be used when available for patients
taking dabigatran. For emergency reversal of dabigatran, the
newly released antidote (idarucizumab) can be used in the
pre- and postoperative settings. Treatment of post-operative
FXa-related bleeding includes PCC, activated PCC (FEI-
BAVR, Shire US Inc., Lexington, MA, USA) and recombi-
nant activated factor VII (rFVIIa), because no speciﬁc
antidote is approved at the moment. These agents have
been found to be effective in some studies (PCC in
volunteer studies, aPCC and rFVIIa mainly in vitro studies)
on FXa inhibitors. Due to the relatively low level of protein
binding, haemodialysis is effective for increasing the
clearance of dabigatran but not for that of FXa-inhibitors
(protein binding 485%).
Based on the available evidence, it is recommended that
DOACs be stopped at least 48 h prior to surgery in patients
having elective cardiac surgery; a longer interval may be
necessary for patients with impaired renal function (Fig. 2).Table 3
Different types of DOACs
Rivaroxaban Apixaban Edoxaban Dabigatran
Target Factor Xa Factor Xa Factor Xa Thrombin
Tmax 2–4 hours 3 hours 1–3 hours 2 hours
Half-life 9–13 hours 9–14 hours 5–11 hours 14–17 hours
Frequency Once daily Twice daily Once daily Once or twice
daily
Renal excretion 66% (half
inactive)
25% 36–45% 80%
Antidote Andexaneta Andexaneta Andexaneta Idarucizumab
Discontinuation 48 hoursb 48 hours 48 hours 48–96 hoursb
EMA: European Medicines Agency; DOACs: direct oral anticoagulants.
aNot yet approved by EMA.
bDiscontinue 448 h if creatinine clearance is 480 ml/min/1.73 m2;
discontinue 472 h if creatinine clearance is 50–79 ml/min/1.73 m2; and
discontinue 496 h if creatinine clearance is o50 ml/min/1.73 m2.4.3. Preoperative AnaemiaRecommendations Classa Levelb RefcOral or intravenous iron alone prior
to cardiac surgery may be
considered in mildly anaemic
patients (women, Hb 100–120 g/l;
men, Hb 100–130 g/l) or in
severely anaemic patients (both
genders, Hb r 100 g/l) to
improve erythropoiesis.IIb CErythropoietin with iron
supplementation should be
considered to reduce postoperative
transfusions in patients with non-
iron deﬁciency (e.g. EPO, vitamin
D or folate acid deﬁciency)
undergoing elective surgery.IIa B 81–83Preoperative erythrocyte transfusion
is not routinely recommended in
preoperative anaemic patients to
prevent postoperative AKI.III CaClass of recommendation.
bLevel of evidence.
cReferences.
AKI: acute kidney injury; EPO: erythropoietin; Hb: haemoglobin.
4.3.1. Implications for Preoperative Anaemia
Background. Anaemia is a frequent comorbid condition in
the elderly patients, and up to 40% of patients present with
mild anaemia (women, Hb 100–120 g/l; men, Hb 100–130 g/l)
or severe anaemia (both genders, Hb r100 g/l) of any cause
prior to cardiac surgery.84 Although anaemia is recognized to
be a predictor of postoperative adverse outcomes, this evi-
dence is mostly based on observational studies.
Description of the Evidence. Preoperative anaemia is asso-
ciated with a worsening of the clinical outcome after cardiac
surgery in terms of blood transfusion requirements, acute kidney
injury (AKI) and death.85–87 Several retrospective studies
showed a signiﬁcant interaction between preoperative anaemia
and blood transfusions on outcome and a pronounced detri-
mental effect of blood transfusions for anaemic patients.88,89
The risk for intraoperative transfusion is signiﬁcantly higher in
mildly anaemic (HR 1.44, 95% CI 1.20–1.73) or severely
anaemic patients (HR 1.81, 95% CI 1.34–2.44).88,89
Derived from retrospective studies, preoperative anaemia is,
therefore, considered a risk factor for adverse clinical out-
comes and transfusion requirements after cardiac surgery.
4.3.2. Iron Supplementation
Background. Supplementation of oral or intravenous iron is
the treatment of choice for iron deﬁciency anaemia. Preopera-
tive iron supplementation may reduce transfusion requirements
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anaemia.
Description of the Evidence. A recent RCT in non-anaemic
patients, based on a 3-arm parallel group design, compared the
effect of 3 preoperative doses of intravenous iron sucrose
(100 mg) and daily oral iron (125 mg) with placebo until
1 month following discharge. No difference was found
between the transfusion requirements of the various groups.90
The PROphylaxis for ThromboEmbolism in Critical Care Trial
(PROTECT) investigated the perioperative administration of
iron isomaltoside (1000 mg) on postoperative Hb levels and
transfusion requirements in non-anaemic patients having
elective surgery.91 Although there was a lower number of
non-anaemic patients in the iron isomaltoside-treated group
compared with the group receiving a placebo 1 month after
surgery (8.0% vs 38.5%, P ¼ 0.019), transfusion requirements
up to 4 weeks after surgery were not different between groups
(13.3% vs 20.0%, P ¼ 0.52). Apart from the signiﬁcant effect
of iron supplementation on stimulation of erythropoiesis, there
are limited data supporting the association between the
administration of iron and reduced postoperative transfusion
requirements in patients with anaemia undergoing cardiac
surgery. The optimal time to start iron therapy before surgery
is unclear from the current evidence.
4.3.3. Erythropoietin
Background. Preoperative anaemia is associated with
adverse outcomes after cardiac surgery in several retrospective
studies.92,93 Erythropoietin (EPO) with or without iron sup-
plementation may be used to treat preoperative anaemia and to
reduce the risk of postoperative transfusion requirements.
Description of the Evidence. Erythropoietin, with or without
iron, has been used to treat noniron deﬁciency anaemia and to
increase red cell mass in patients who refuse blood transfu-
sions or who are at high risk of postoperative anaemia, such as
patients with renal failure.9,94,95 Administration of EPO
(80 000 IU) and oral iron (40 mg) or iron alone in 600 mildly
or non-anaemic patients reduced the perioperative PRBC
transfusion requirements in patients treated with EPO more
than in controls (17% vs 39%, P o0.0005), but this difference
was diminished after controlling for baseline Hb levels.81 In
320 patients undergoing off-pump CABG surgery, preopera-
tive high-dose EPO treatment (cumulative dose of 52 000 IU)
starting 2 days prior to and lasting until 2 days after surgery
was compared to the effects of placebo.82 Postoperative
transfusion requirements were lower in the EPO group
compared with the placebo group (0.33 vs 0.76 units per
patient, P ¼ 0.008). A single dose of EPO (500 IU/kg) with
iron sucrose (200 mg) 1 day prior to surgery in primary heart
valve procedures reduced transfusion requirements during
surgery until 4 days postoperatively compared with the control
group (59.5% vs 86.5%, P ¼ 0.009).83 In all studies, the
investigators were blinded to the study treatment (single
blinded).In summary, EPO with or without iron supplementation
should be considered in patients with non-iron deﬁciency
undergoing elective surgery to reduce postoperative transfu-
sions. Even an EPO infusion in the days before surgery may
have beneﬁts in terms of transfusion requirements. It should be
noted that, in part, data showing a treatment beneﬁt for EPO
were obtained from non-anaemic treated patients undergoing
cardiac surgery.
4.3.4. Blood Transfusion to Treat Preoperative Anaemia
Background. Preoperative blood transfusions to treat anae-
mia are frequently used to symptomatically treat low Hb
values. Transfusion prior to cardiac surgery or with initiation
of CPB has been suggested for patients with pre-existing
anaemia.
Description of the Evidence. One small RCT investigated the
effect of preoperative PRBC transfusion in anaemic patients on
intraoperative transfusion requirements and AKI as out-
comes.96 Prophylactic transfusion of 2 PRBC units was
associated with a reduced rate of intraoperative transfusion
[0 (0–2) vs 2 (1–4) units, P o0.001] compared with standard
care but not with a reduced rate of AKI.96 Given the lack of
additional published evidence, an expert consensus was
reached by the guideline committee against the routine use
of transfusions for patients with preoperative anaemia. How-
ever, in the case of emergency surgery and life-threatening
anaemia, it is legitimate to use preoperative blood transfusions
to increase Hb levels.
5. Intraoperative Management
Intraoperative preservation of patient haemostasis is a
multidisciplinary and multifactorial challenge. Even though
the surgeon applies meticulous haemostasis and patience with
respect to clot formation, these measures are only effective
when paralleled by interventions that minimize haemodilution,
normothermia, appropriate anticoagulation and haemostatic
monitoring during the procedure.
5.1. Surgical Techniques
Special surgical or perfusion techniques, such as off-pump
CABG, minimally invasive extracorporeal circulation circuits
(MiECC) and minimally invasive cardiac surgery are not
universally implemented. These procedures might only be
safe and efﬁciently performed when integrated into the daily
clinical routine. Therefore, any recommendations regarding the
use of these techniques are addressed to centres with adequate
experience in these procedures. However, especially for
severely anaemic patients, it is highly recommended that the
members of the multidisciplinary team (cardiologists, sur-
geons, anaesthesiologists and perfusionists) discuss optimal
treatment strategies, including surgical techniques, the limita-
tions of haemodilution and improved CPB systems to avoid
massive transfusions and bleeding.
Recommendations Classa Levelb Refc
It is recommended that the members
of the multidisciplinary teamd
discuss the optimal surgical strategy
based on clinical status,
comorbidities, bleeding risk and
team expertise.
I C
Off-pump CABG surgery may be
considered in selected patientse to
reduce perioperative transfusions.
IIb B 97,98
MiECC systems should be considered
over standard conventional CPB
systems to reduce perioperative
transfusions.
IIa B 99,100
Minimally invasive heart valve
surgery may be considered to reduce
blood loss and the need for
transfusions.
IIb B 101–103
Routine use of topical sealants in
cardiac surgery is not recommended.
III B 104
Topical sealants may be considered in
clinical situations where
conventional approaches to surgical
and medical improvement of
haemostasis and where bleeding
problems are more local than
generalized.
IIb C
aClass of recommendation.
bLevel of evidence.
cReferences.
dSurgeons, cardiologists, anaesthesiologists and perfusionists.
eDialysis-dependent patients, patients operated on under DAPT and anaemic
patients with low body surface area.
CABG: coronary artery bypass grafting; CPB: cardiopulmonary bypass;
DAPT: dual antiplatelet therapy; MiECC: minimally invasive extracorporeal
circulation circuits.
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Background. Several hypothetical mechanisms by which off-
pump CABG surgery might reduce bleeding and/or the need
for blood product transfusions, including lower dosing of
systemic heparin, the standard use of cell saving and the fact
that haemodilution and blood trauma caused by CPB, are
obviated with this technique.
Description of the Evidence. There are no RCTs comparing
off-pump and on-pump CABG where bleeding, transfusion or
the need for reoperation was the primary end point; the data
are therefore extrapolated. A meta-analysis comprising 102
RCTs compared off-pump with on-pump CABG in 19 101
patients.98 The secondary end points of PRBC transfusion
(OR 0.49, 95% CI 0.33–0.72) and blood product transfusion
(OR 0.66, 95% CI 0.55–0.81) were signiﬁcantly lower in
patients having off-pump than in those having on-pump
CABG surgery, without differences in re-exploration forbleeding.98 However, a large variability across studies was
observed, suggesting that such a beneﬁt could not be repro-
duced in several of the RCTs included. A recent meta-analysis
of RCTs showed similar results97 but was also confounded by
a high grade of heterogeneity for transfusion requirements and
chest tube drainage among RCTs. In the 2 largest RCTs (the
Coronary Artery Bypass Surgery [CABG] Off or On Pump
Revascularization Study [CORONARY]105 and the German
Off-Pump Coronary Artery Bypass Grafting in Elderly
Patients [GOPCABE] trial106), off-pump surgery was asso-
ciated with lower transfusion rates (50.7% vs 63.3% and
56.3% vs 62.7%, respectively; both P o0.001). However, in
these RCTs, physicians were not blinded to treatment alloca-
tion, and the transfusion protocol was not prespeciﬁed. There-
fore, the treatment received might have inﬂuenced the decision
to transfuse.
In summary, off-pump surgery may be considered a surgical
technique that is associated with fewer transfusion require-
ments than on-pump surgery.
5.1.2. Minimally Invasive Extracorporeal Circulation
Background. The common features of MiECC are a small
priming volume (~600–750 ml), a reduced artiﬁcial surface
due to the absence of the venous reservoir, a biocompatible
coated system and a centrifugal pump. Systems are completely
closed to avoid blood–air contact, and they include the
separation of shed blood.107
Description of the Evidence. RCTs comparing MiECC
versus conventional CPB were too underpowered to detect a
signiﬁcant difference in transfusion rates. The available meta-
analyses99,100 show a reduced rate of transfusion with MiECC
but include open studies and studies without a predeﬁned
transfusion protocol. The type of circuit used may also have
inﬂuenced the decision to transfuse. These aspects limit the
generalizability of current comparisons. Two recent meta-
analyses compared MiECC with conventional CPB proce-
dures.99,100 An analysis of the results of 24 studies (n ¼ 2770)
showed that the use of MiECC was associated with a reduced
risk of PRBC transfusion (OR 0.24, 95% CI 0.16–0.37;
P o0.001) but without a reduction in reoperations for
bleeding.99 In a meta-analysis that assessed 29 studies with
2335 patients, the use of MiECC resulted in a signiﬁcant
reduction in the risk of transfusions (OR 0.35, 95% CI 0.23–
0.53), whereas reoperation rates for persistent bleeding revealed
no difference.100
In summary, the use of MiECC systems, when compared
with conventional CPB systems, is associated with a reduction
in PRBC transfusions. Therefore, in an attempt to reduce
allogeneic blood transfusions, MiECC systems can be con-
sidered. However, the use of MiECC systems does not
contribute towards reducing reoperation rates for bleeding.
5.1.3. Minimally Invasive Surgery
Background. Minimally invasive heart valve surgery may
play a role in reducing the need for transfusion and reoperation
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tissue dissection and retraction to open up the surgical ﬁeld.
Description of the Evidence. The available evidence consists
almost entirely of observational studies and should not be
considered deﬁnitive. The 2010 International Society for
Minimally Invasive Cardiothoracic Surgery consensus state-
ment concluded that the risk of transfusion for PRBCs was
reduced after minimal mitral valve surgery compared with the
conventional approach (difference of -1.9 units; 95% CI -2.5 to
-1.2 units), but reoperation for bleeding was not
different between the groups.102 A systematic review of mitral
valve surgery through a right lateral minithoracotomy versus
sternotomy identiﬁed a total of 45 studies, including
3 RCTs.101 The minimally invasive approach was associated
with a small reduction in bleeding (mean difference -142.1 ml,
95% CI -199.2 to -85.1 ml) and risk for transfusion (RR 0.67,
95% CI 0.51–0.88). However, pooled data from the small
RCTs showed that minimally invasive surgery did not reduce
total blood loss (mean difference -149 ml; 95% CI -491 to 193
ml) or the incidence of transfusion (RR 0.94, 95% CI 0.61–
1.45). In a systematic review on aortic valve replacement
through minimally invasive access versus full sternotomy,103
pooled data from 3 RCTs showed no difference in the rate of
blood product transfusions (RR 0.77, 95% CI 0.58–1.03),
whereas pooled data from observational studies suggested
otherwise. Minimally invasive heart valve surgery is practised
in high volumes in only a limited number of centres.
Until minimally invasive valve surgery becomes more
widely adopted and large RCTs are performed, there is not
enough evidence to suggest broad adaption for the purpose of
blood conservation.
5.1.4. Topical Haemostatics
Background. In addition to systemic haemostatic action,
topical haemostatic agents are locally applied and include
haemostatic sealants and topical antiﬁbrinolytic agents [aproti-
nin, tranexamic acid (TXA) and E-aminocaproic acid
(EACA)].108,109 Passive haemostatic agents that activate plate-
lets, including collagen, gelatines and regenerated oxidized
cellulose, do not contain biologically active clotting factors.
The last category of topical agents includes synthetic (cyanoa-
crylates) and semi-synthetic (glutaraldehyde–albumin) sealants,
which have sealing properties through a rapid polymerization
process without having intrinsic haemostatic activity.
Description of the Evidence. A Cochrane systematic
review108 on 18 RCTs comparing ﬁbrin sealant versus no
ﬁbrin sealant concluded that ﬁbrin sealants are efﬁcacious in
reducing both postoperative blood loss (mean difference -161
ml, 95% CI -98.25 to -224.53) and perioperative exposure to
allogeneic PRBC transfusions (RR 0.63, 95% CI 0.45–0.88).
However, this review was limited by the inclusion of only
1 cardiac surgery study and RCTs with small sample sizes. A
meta-analysis109 including 8 RCTs (n ¼ 622 patients) showed
that topical antiﬁbrinolytic agents reduced the amount of 24-h
chest tube blood loss by 220 ml (95% CI -318 to -126) andresulted in a saving of 1 PRBC unit per patient (95% CI -1.54
to -0.53). However, high heterogeneity among RCTs was
found. No adverse effects were reported following topical use
of the medications. A more recent Cochrane systematic
review110 including 7 RCTs (n ¼ 511) supported a protective
role of topical antiﬁbrinolytic agents in cardiac surgery (RR
0.63, 95% CI 0.61–0.66), but the overall quality of the studies
included was low. A recent RCT including off-pump CABG
patients did not ﬁnd any beneﬁt from topical EACA regarding
postoperative bleeding and transfusion.111
Based on the available evidence, the routine use of topical
sealants in cardiac surgery is not recommended and may only
be considered in cases of persistent bleeding where the
bleeding is localized.
5.2. Cardiopulmonary BypassRecommendations Classa Levelb RefcImplementation of institutional
measures to reduce haemodilution
by ﬂuid infusion and CPB during
cardiac surgery to reduce the risk
of bleeding and the need for
transfusions is recommended.I CThe use of a closed extracorporeal
circuit may be considered to
reduce bleeding and transfusions.IIb B 112,113The use of a biocompatible coating to
reduce perioperative bleeding and
transfusions may be considered.IIb B 114–116The routine use of cell salvage
should be considered to prevent
transfusions.IIa B 117–119(Modiﬁed) ultraﬁltration may be
considered as part of a blood
conservation strategy to minimize
haemodilution.IIb B 120–122Retrograde and antegrade autologous
priming should be considered as
part of a blood conservation
strategy to reduce transfusions.IIa A 123–125Normothermia during CPB
(temperature 436o C) and
maintenance of a normal pH
(7.35–7.45) may contribute to a
reduced risk of postoperative
bleeding.IIb B 126,127aClass of recommendation.
bLevel of evidence.
cReferences.
CPB: cardiopulmonary bypass.
5.2.1. Closed versus Open Cardiopulmonary Bypass
Background. The contact of blood with ambient air in the
reservoir and in other parts of the circuit in extracorporeal
circulation (ECC) is regarded as one of the several causes of
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minimize the blood/air interface and platelet activation and are
an integral part of MiECC systems but result in more
complicated perfusion that requires active trapping of air
bubbles.129 The use of cardiotomy suction requires a separate
reservoir, and vacuum-assisted venous drainage cannot be
applied to the collapsible reservoir bag.
Description of the Evidence. A large number of studies
combined several components of blood conservation, includ-
ing closed circuits. Some studies combined the elimination of
cardiotomy suction with the use of a closed system or
investigated the combined effect of surface coating, a closed
system and different pumps.113,130 In an RCT, closed systems
had no advantage over open systems for patient haemosta-
sis.113 In a small, single-centre RCT, a closed system reduced
transfusion requirements compared with an open system (378
7 364 ml vs 717 7 486 ml; P ¼ 0.003).112 Taken together,
the use of a closed ECC may be considered to reduce bleeding
and transfusions, but adequately sized RCTs on closed versus
open systems are lacking.
5.2.2. Biocompatible Coating
Background. Biocompatible coating of tubing and oxygena-
tor mimics the natural endothelial lining of blood vessels and
improves the haemocompatibility and hydrophilicity of the
system, thereby reducing the risk of clot activation. Among
others, biocompatible coatings include ionic or covalent
heparin bonding, poly(2-methoxyethylacrylate) (PMEA) and
phosphorylcholine. The effect of the biocompatible coating of
the ECC on bleeding and transfusion requirements is still
under investigation.
Description of the Evidence. A systematic review and meta-
analysis published in 2009 of 36 RCTs issued between 1992
and 2006 showed that the use of any biocompatible coating
reduced the risk of PRBC transfusion (OR 0.8, 95% CI 0.69–
0.93) compared with the use of a non-coated circuit.114 A more
recent systematic review of 14 RCTs concluded that second
and third-generation heparin-coated circuits only showed
superiority on perioperative blood loss to non-coated circuits
in about 50% of the studies included.116 A large RCT showed
that the combination of heparin-coated circuits with low or
conventional dose heparinization was associated with a
reduced 12-h blood loss compared with non-coated circuits
(mean volume 382 vs 431 vs 457 ml; P o0.01,
respectively).131
Other studies showed that the use of phosphorylcholine-
coated circuits might contribute to less perioperative blood loss
and fewer transfusion requirements.132–134 In 2 small studies
comparing the effect of PMEA, phosphorylcholine and
heparin-coated circuits,135,136 only 1 study showed that PMEA
coating was associated with fewer platelet transfusions com-
pared with heparin coating.135
Based on the available data, the use of a biocompatible
coating may be considered as part of a PBM programme to
reduce perioperative bleeding and transfusions.5.2.3. Cell Salvage
Background. Cell salvage of operative blood loss and
residual blood from the circuit after CPB may contribute to
a reduction in the use of allogeneic blood products, especially
PRBCs. A speciﬁc rationale for cell salvage is its use during
CPB instead of cardiotomy suction, since the retransfusion of
whole blood using cardiotomy suction through the ECC may
contribute to systemic inﬂammation and bleeding.
Description of the Evidence. A Cochrane review showed that
the use of cell salvage reduced the risk of PRBC transfusions
(RR 0.78, 95% CI 0.68–0.91) during cardiac surgical proce-
dures.117,137 In a meta-analysis comparing cell salvage with
cardiotomy suction, it was found that cell salvage reduced the
risk of any blood transfusion (OR 0.63, 95% CI 0.43–0.94)
without increasing adverse effects or bleeding.138 Recent
studies conﬁrmed that the use of cell salvage is efﬁcient in
reducing allogeneic blood exposure.118,119,139
Cardiotomy suction might be associated with thrombin
generation and neutrophil and platelet activation and could
contribute to higher transfusion requirements.9 The ameliora-
tion of inﬂammation by the removal of activated plasma
through the washing of shed blood has repeatedly been
demonstrated.140–142 Cell saver processing of cardiotomy
suction blood only has no beneﬁcial effect on blood conserva-
tion and increases the use of fresh-frozen plasma (FFP)
transfusions.138,143,144 Extending the use of cell salvage to
the postoperative phase may show additional beneﬁts,143
although others did not conﬁrm this.118 Moreover, large
volumes of cell-salvaged blood may lead to a relative loss of
plasma and may result in impaired coagulation.145 Therefore,
it may be concluded that the balance between a positive effect
of cell salvage on transfusion requirements and a reduction of
negative systemic effects (versus the inherent loss of plasma,
platelets and leucocytes) depends on the quantity of the
salvaged blood.
In the postoperative period, tube drainage and the washing
of blood may be implemented to reduce postoperative blood
transfusions. The British National Institute for Health and
Clinical Excellence conducted an extensive review of the
literature and several meta-analyses for postoperative cell
salvage.146 In cardiac surgery, the absolute risk of being
exposed to allogeneic blood was approximately 15.6% (95%
CI 7.4–21.4%) lower in patients receiving postoperative cell
salvage and 1 unit less of allogeneic blood. Postoperative cell
salvage resulted in lower rates of infection, lower mortality
rates and shorter hospital stays. Unwashed salvaged blood
from postoperative surgical drains contains higher concentra-
tions of inﬂammatory mediators, ﬁbrin split products, inter-
leukins, fat emboli and complement factors and may increase
the risk of inﬂammatory complications.147
In summary, the routine use of cell salvage should be
considered to prevent transfusions, but the retransfusion of
large volumes of cell salvaged blood (41000 ml) may impair
coagulation. Overall, postoperative cell salvage and reinfusion
of washed erythrocytes may be considered to reduce transfu-
sions in patients with bleeding.
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Background. The total volume of blood during CPB can be
controlled using ultraﬁltration. In modiﬁed ultraﬁltration,
excess ﬂuid is discarded from the remaining blood after the
termination of ECC.
Description of the Evidence. Ultraﬁltration and modiﬁed
ultraﬁltration are accompanied by removal of mediators of
inﬂammation, which may also lead to improved haemostasis. In
a meta-analysis, it was shown that ultraﬁltration, and particu-
larly modiﬁed ultraﬁltration, was associated with a reduction in
postoperative blood transfusions (-0.73 units; 95% CI -1.16 to
-0.31).121 In a large RCT, patients subjected to ultraﬁltration
showed lower transfusion requirements compared to patients in
whom ultraﬁltration was not implemented.122
Although most studies hinted at a beneﬁcial effect of
ultraﬁltration on postoperative transfusion requirements, espe-
cially in the presence of preoperative anaemia, the evidence is
based on small underpowered studies, with transfusion
requirements as a secondary end point.
5.2.5. Retrograde and Antegrade Autologous Priming
Background. The priming of the ECC with an asanguineous
ﬂuid results in haemodilution and increases the risk of blood
transfusion, particularly in patients with a small body surface
area.148 Antegrade autologous priming and retrograde auto-
logous priming (RAP) are simple, inexpensive, efﬁcient ways
to address the issue of haemodilution.
Description of the Evidence. Most of the available literature on
this topic refers to studies in which several features of minimized
bypass systems were combined. However, some smaller RCTs
focusing on RAP have been performed. The largest meta-analysis
concluded that RAP signiﬁcantly reduced transfusion requirements
(RR 0.53, 95% CI 0.43–0.66; P o0.001).123 Similar ﬁndings
were demonstrated in the meta-analysis of 6 RCTs in which
patients treated with RAP received signiﬁcantly fewer PRBC
transfusions during hospitalization (weighted mean difference -0.60
units, 95% CI -0.90 to -0.31; P ¼ 0.001).124 These ﬁndings were
conﬁrmed in an RCT with 120 patients and a body surface area
o1.5 m2, showing that RAP resulted in a marked reduction of
haemodilution and signiﬁcantly reduced transfusion require-
ments.148 On the basis of the evidence, RAP and antegrade
autologous priming should be considered as part of a blood
conservation strategy to reduce transfusions.
5.2.6. Coagulation-Friendly Environment
Background. The enzymatic process of coagulation requires
an optimal temperature and acidity level. Both hypothermia
and acidosis may reduce the thrombin-generation capacity,
thereby impairing patient haemostasis. The number of studies
focusing on the association of hypothermia or acidosis with
postoperative bleeding is limited.
Description of the Evidence. Hypothermia in cardiac surgery
is used to enhance myocardial and end-organ preservation,
particularly during CPB. However, hypothermia is alsoassociated with coagulopathy. In an RCT of patients who
had CABG surgery, it was shown that hypothermia (34o C)
was not associated with greater 12-h blood loss compared with
normothermic patients (37o C).149 A retrospective analysis of
patients having off-pump CABG surgery showed that transfu-
sion rates were higher in patients exposed to mild hypothermia
(o36oC).127 One retrospective study investigated the associa-
tion between acidosis, post-surgery acidosis and postoperative
bleeding,126 showing that even a moderate degree of acidosis
(pH o7.35) and hyperlactataemia (lactate 44.0 mmol/l) was
associated with a signiﬁcantly higher volume of postoperative
chest drainage compared with no acidosis/hyperlactataemia 12
h after surgery (mean blood loss 576 vs 406 ml; P ¼ 0.001).
Despite the lack of large, prospective studies on temperature
management and the maintenance of pH during cardiac
surgery, there is general agreement that the coagulation system
requires normal physiological circumstances, including nor-
mothermia and a pH nearly 7.4.
5.3. Intraoperative AnticoagulationRecommendations Classa Levelb RefcHeparin level-guided heparin
management should be considered
over ACT-guided heparin
management to reduce bleeding.IIa B 150–152Heparin level-guided protamine
dosing may be considered to reduce
bleeding and transfusions.IIb B 153Protamine should be administered in a
protamine-to-heparin dosing ratiod
o1:1 to reduce bleeding.IIa B 154AT supplementation is indicated in
patients with AT deﬁciency to
improve heparin sensitivity.I B 155,156AT supplementation is not rec-
ommended to reduce bleeding
following CPB.III CIn patients with HIT antibodies for
whom surgery cannot be postponed,
anticoagulation with bivalirudin
should be considered when the
bleeding risk is acceptable. The use
of heparin in the pre- and
postoperative periods should be
avoided.IIa CaClass of recommendation.
bLevel of evidence.
cReferences.
dProtamine-to-heparin dosing ratio based on the initial heparin dose.
ACT: activated clotting time; AT: antithrombin; CPB: cardiopulmonary
bypass; HIT: heparin-induced thrombocytopenia.
5.3.1. Heparin and Anticoagulation Monitoring
Background. UFH binds to antithrombin (AT), which then
potentiates the inactivation of thrombin and FXa by AT up to a
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speciﬁc characteristics157 and is assessed by the whole-blood
activated clotting time (ACT) test. Target ACT values range
from 300 to 600 s depending on the methods used to measure
the ACT or due to different heparin dosing strategies. More-
over, the variation in the efﬁcacy of different heparins may
need individual anticoagulation strategies.
UFH is usually dosed based on patient body weight (300–
600 U/kg), followed by additional doses in the case of a
periprocedural decrease in the ACT. Heparin resistance and
postoperative heparin rebound are major limitations of this
strategy. Heparin resistance may lead to insufﬁcient antic-
oagulation during the procedure, whereas heparin rebound
may contribute to post-surgical bleeding.
Description of the Evidence
Individualized Heparin Management. Individualized
heparin management or titration based on a dose–response
test is based on the use of the HMS/HepCon (Medtronic,
Minneapolis, MN, USA), Hemochron RxDx (Accriva Diag-
nostics, San Diego, CA, USA) or anti-Xa measurements in
addition to the ACT. The number of RCTs that focus on the
advantages of heparin dose–response implementation is, how-
ever, limited. In most studies, the use of a heparin titration
device resulted in an increased heparin dose and a decrease in
the protamine dose. In most studies, this situation is associated
with decreased blood loss and transfusion requirements as well
as with higher platelet counts at the end of the opera-
tion.150,151,153,158–160 In contrast, others did not show favour-
able results for blood loss and transfusion requirements when
heparin titration was compared with an ACT-based proto-
col.152,161–163 Due to the lack of perioperative bleeding and
transfusion rates as primary end points in these studies, larger
multicentre RCTs are required to determine the added value of
individual heparin management. Alternative methods of
heparin management and anticoagulation monitoring during
ECC consist of the determination of anti-factor Xa activity.
The determination of thrombin levels could be promising, but
it is not useful with high concentrations of heparin and is
currently not available as a bedside clinical test.
Heparinization Algorithms. There is increasing interest in the
application of heparinization algorithms to tailored heparin and
protamine management in cardiac surgery. Application of
these algorithms might contribute to improved anticoagulation
strategies and PBM, especially in heparin-resistant patients,
but RCTs evaluating the effectiveness of these models are
currently lacking.
Measures to Prevent Heparin Rebound. Heparin rebound is
the result of residual heparin blood concentrations in the
postoperative phase. Although most of the literature on this
topic originates from the 1980s to the 1990s, the recent
literature can be divided into studies focusing on the presence
of residual heparin in the blood following weaning from CPB or
on the occurrence of postoperative bleeding associated with
residual heparin. There is only 1 comparative study that showedthat protamine infusion (25 mg/h for 6 h) to neutralize residual
heparin resulted in reduced 12-h blood loss compared with the
control subjects (525 7 322 vs 608 7 385 ml, respectively;
P o0.05) but without affecting transfusion rates.164 The study
was, however, limited by the possibility of administering
additional protamine to normalize ACT values to preheparin
values, which occurred more frequently in the control group and
might have enhanced postoperative bleeding.164
In summary, a statement regarding optimal heparin antic-
oagulation management is limited by the lack of prospective
and comparative studies. Heparin level-guided heparin man-
agement should, however, be considered over ACT-guided
heparin management to reduce bleeding, especially in patients
who are resistant to heparin.
5.3.2. Protamine
Background. The heparin–protamine complex leads to the
dissociation of heparin from AT and restoration of the procoa-
gulant properties of blood. Inadequate protamine dosing may,
however, inﬂuence patient haemostasis and the risk of post-
operative bleeding. The dose of protamine is usually based on
the initial or total administered dose of heparin throughout the
procedure. Protamine administration may be associated with
immunological and inﬂammatory alterations and may induce
hypotension, bradycardia, pulmonary vasoconstriction and aller-
gies, which can, in most cases, be prevented by slow infusion
rates, prophylactic use of ASA or an antihistaminic drug.
Description of the Evidence. In a small RCT, protamine
dosing based on the initial heparin dose resulted in prolonged
clotting times and microvascular bleeding compared with
protamine dosing based on the measured heparin concentration
following CPB.165 In a second RCT, a protamine-to-heparin
dosing ratio of 1.3 over the total heparin dose was associated
with signiﬁcantly more postoperative bleeding (615 ml, 95% CI
500–830 vs 470 ml, 95% CI 420–530; P ¼ 0.02) compared
with a dosing ratio of 0.8, whereas post-protamine ACT levels
were comparable among the groups.154 None of the patients
showed signs of heparin rebound. A recent RCT in patients
having CABG showed that a protamine-to-heparin dosing ratio
o0.6 was associated with signiﬁcantly more blood loss within
12 h after surgery [420 ml (interquartile range 337–605 ml) vs
345 ml (interquartile range 230– 482 ml); P ¼ 0.0041], but no
difference in PRBC transfusion was noted (2.3 units vs 2.7 units;
P ¼ 0.83) compared to patients subjected to a ratio 40.8.152
Ideally, protamine should be administered in a dose that
matches actual heparin levels after the termination of ECC. It
is advised not to exceed a protamine dose in a 1:1 ratio to the
initial heparin bolus, because protamine overdosing might be
associated with perioperative bleeding and enhanced transfusion
requirements.
5.3.3. Antithrombin
Background. Patients resistant to heparin may have insufﬁ-
ciently low AT levels or dysfunctional AT and may require
additional heparin dosing to reach the target ACT with a
concomitant risk of residual heparin in the postoperative
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AT supplementation before CPB.
Description of the Evidence. In a small RCT (n ¼ 20),
preoperative AT supplementation (50 U/ kg) was not associated
with reduced post-operative bleeding compared with the controls.
At 6 and 12 h following surgery, median blood loss was similar
between the groups (P ¼ 0.33 and P ¼ 0.24, respectively), with
a higher variation in the AT group.166 In heparin-resistant patients
(deﬁned as those demonstrating an inability to reach a target ACT
of 480 s upon the administration of 300 þ 100 IU/kg heparin), a
single bolus of AT (75 U/kg) was associated with a reduced use
of FFP. Administration of AT compared with placebo tended to
increase 12-h postoperative bleeding (mean blood loss 1290 vs
756 ml; P ¼ 0.05), without differences in transfusion rates
between the groups.155 In a second RCT, AT supplementation
also resulted in higher bleeding rates 12 h after surgery compared
with the controls (mean blood loss 450 vs 350 ml, respectively;
P ¼ 0.011).167
In summary, AT supplementation is indicated in patients
with AT deﬁciency to improve heparin sensitivity but should
not be used prophylactically to reduce bleeding following
CPB. FFP may be considered an alternative to AT supple-
mentation in patients with AT deﬁciency to improve heparin
sensitivity.
5.3.4. Heparin-Induced Thrombocytopenia Anticoagulation
Management
Background. In patients with Type 2 heparin-induced throm-
bocytopenia (HIT), antibodies are generated against the anti-
gen complex of heparin and platelet factor 4. This antigen–
antibody complex may cause haemostatic and platelet activa-
tion and severe thromboembolism, which is diagnosed by
highly speciﬁc platelet function tests or heparin–platelet factor
4 antibody enzyme-linked immunosorbent assays and platelet
serotonin release assays.168 Usually, HIT antibodies develop
after 7–14 days of exposure to heparin with a half-life of 40–
100 days. Newer generation ELISA tests are immunoglobulin
G-speciﬁc, whereas older assays also measured immunoglo-
bulin M and immunoglobulin A antibodies, resulting in a
signiﬁcant overdiagnosis of HIT.168–170 When HIT is diag-
nosed, heparin should be replaced by an alternative antic-
oagulant. The risks of alternative anticoagulation procedures,
including increased bleeding, have to be balanced against
potential HIT-associated complications.
Description of the Evidence. Direct thrombin inhibitors like
bivalirudin or argatroban can be used as an alternative antic-
oagulant during CPB. Bivalirudin is the only agent that has
been studied in prospective multicentre trials in patients with
and without HIT undergoing on-pump and off-pump cardiac
surgery.171–174 In a cardiac surgery trial in patients without
HIT, safety data for bivalirudin were almost comparable to
those of the competitor heparin–protamine.173 Bivalirudin has
a short elimination half-life (rv25 min) and no speciﬁc
antidote. Due to its unique pharmacological characteristics,
the surgical and perfusion strategies must be adjusted for thetarget ACT, use of prime volume and cardioplegia to avoid the
stagnation of blood in the CPB circuits.175
Another strategy is to combine heparin with a potent
shortacting antiplatelet agent, such as iloprost or tiroﬁban, to
inhibit or attenuate the HIT reaction.176,177 However, when the
effects of iloprost or tiroﬁban are eliminated, patients may
again be at risk of developing HIT-associated complications.
There are no sufﬁcient data to support reduction of HIT
antibodies via perioperative plasmapheresis.178,179
In summary, in patients with HIT antibodies, in whom
surgery cannot be postponed, bivalirudin anticoagulation may
be considered when the bleeding risk is acceptable. The use of
heparin in the pre- and postoperative periods should be
avoided. If bivalirudin is deemed to be associated with a high
risk of bleeding, heparin in combination with an antiplatelet
agent may be considered.
5.4. Intravascular VolumeRecommendations Classa Levelb RefcThe use of goal-directed
haemodynamic therapy to reduce
transfusions is not recommended.III CThe use of modern low-molecular
weight starches in priming and non-
priming solutions to reduce bleeding
and transfusions are not
recommended.III CLimitation of haemodilution is
recommended as part of a blood
conservation strategy to reduce
bleeding and transfusions.I B 180–182Preoperative autologous blood
donation in patients with high
haemoglobin levels (4110 g/l) may
be considered to reduce
postoperative transfusions.IIb B 183–185Acute normovolaemic haemodilution
may be considered to reduce
postoperative transfusions.IIb B 186aClass of recommendation.
bLevel of evidence.
cReferences.
5.4.1. Goal-Directed Haemodynamic Therapy
Background. Goal-directed therapy is deﬁned as the use of
ﬂuids, inotropes, vasoconstrictors and/or blood transfusions to
target systemic haemodynamic goals, such as blood pressure
or cardiac output, which improve the perfusion and oxygena-
tion of tissues.
Description of the Evidence. An RCT combined with a
systematic review187 was designed to investigate the effect of
goal-directed therapy on outcomes in high-risk cardiac surgical
patients (EuroSCORE 46 and/or with recent MI o14 days).
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more intravenous ﬂuids compared with the controls, there were
no differences in intraoperative PRBC transfusion volumes
between the groups [0 (0) units vs 1 (1.6) units, respectively;
P ¼ 0.32).187 There are currently no other studies available in
this area that focus on bleeding and blood transfusions.
Low blood pressure is, among other interventions, treated
by vasopressors, but the rise in blood pressure might con-
tribute to enhanced blood loss. On the other hand, maintaining
the mean arterial pressure using a vasoconstrictor mitigates the
haemodilution associated with anaesthesia and CPB.188 One
RCT showed that goal-directed therapy using ﬂuids, inotropes
and vasopressor therapy did not affect the secondary end point
transfusion requirements, despite there being more vasopressor
therapy than in the control group.189 Given the availability of
limited data, it is not possible to reach evidence-based
conclusions on the beneﬁts of goal-directed ﬂuid therapy in
this setting.
5.4.2. Use of Crystalloids and Colloids
Background. There is no consensus regarding optimal ﬂuid
strategies in cardiac surgery, but it has been suggested that the
use of hydroxyethyl starches (HES) may be associated with
increased perioperative blood loss. Most of the available RCTs
are limited by sample size and focus on the effect of different
priming solutions on patient haemostasis, with bleeding or
transfusion requirements as a secondary end point.
Description of the Evidence
Priming Solutions. In studies addressing the impact of the
type of priming solution on postoperative bleeding and blood
product transfusion as secondary end points, a comparison of
6% HES 130/0.4 (mean molecular weight 130 kDa; degree of
substitution) with 6% HES 400/0.7 prime with gelatine
prime,190 albumin prime191,192 or Ringer’s acetate193 was
made. There was no effect of 6% HES 130/0.4 on blood loss
or transfusion requirements. Two studies showed a reduction
in postoperative blood loss when albumin was added to an
HES 130/0.4 prime194 or compared to 6% HES 200/0.5 with
3.5% gelatin.195 However, a review of prospective studies that
compared different priming solutions with blood loss and/or
transfusion requirements as primary end points reported no
difference in postoperative blood loss when different HES
solutions were evaluated.196–199
Volume Therapy. Two studies investigated the impact of
different intraoperative volume therapy strategies on post-
operative bleeding and/or transfusion as the primary end point.
A comparison of 1 litre of 6% HES with 5% albumin during
off-pump CABG procedures was associated with signiﬁcantly
more 12-h chest drainage volume (mean blood loss 732 vs 563
ml; P o0.001).200 In contrast, 6% HES 130/0.4 vs 3.5%
gelatine showed no differences in total blood loss (mean blood
loss 19.4 vs 19.2 ml/kg).201 In a 3-armed study, there was no
difference in 24-h blood loss when 5% albumin or Ringer’s
lactate was compared with 6% HES 130/0.4 (mean blood loss
835 vs 670 vs 700 ml, respectively; P ¼ 0.085). However, the
transfusion rates of PRBC were higher in the albumin andHES groups compared with that of Ringer’s lactate (58% vs
61% vs 24%, respectively; P ¼ 0.0013), with the highest
creatinine levels reported for the HES group.202
In summary, in studies designed to show a difference in
blood loss or transfusion requirements, distinct priming solu-
tions or perioperative volume strategies revealed comparable
results. However, due to the suggestion that the use of HES
may be associated with kidney failure and increased mortality
rates, starches are decreasingly used as volume therapy during
cardiac surgery. It is therefore not recommended to use
modern low-molecular-weight starches in priming and non-
priming solutions to reduce bleeding and transfusions.
5.4.3. Haemodilution and Cardioplegia
Background. Haemodilution is advantageous to a certain
degree, because it lowers blood viscosity and may improve
microcirculatory perfusion. However, haemodilution also leads
to a reduced concentration of coagulation factors and blood
cells during and following ECC, which may have implications
for postoperative haemostasis and organ function.
Description of the Evidence. Publications from large data-
base studies have shown that low haematocrit values are
associated with increased morbidity182 and in-hospital
deaths.203 One meta-analysis showed that the use of mini-
mized circuits reduces haemodilution, postoperative bleeding
and transfusion requirements.100 Two studies focused on
haemodilution independent of the use of MiECC systems by
implementing a multimodality blood conservation scheme or
restricting intravenous ﬂuids during surgery.180,181 In both
studies, a marked reduction in the number of transfusions with
increased haematocrit values was achieved.180,181
In conclusion, limitation of haemodilution is recommended
as part of a blood conservation strategy to reduce bleeding and
transfusions.
5.4.4. Predonation of Blood
Background. Preoperative autologous blood donation in the
hours, days or weeks before surgery may reduce the number of
allogeneic blood transfusions. Preoperative blood donation is
limited to patients with relatively high Hb and haematocrit
levels and with a relatively large body surface area without
coagulation abnormalities.
Description of the Evidence. A large retrospective study
showed that autologous blood donation in elective CABG or
valve surgery was associated with a lower occurrence of
allogeneic blood transfusion and cost-effectiveness.184 How-
ever, the study lacked statistical adjustment for confounding
factors.184 In a matched-pair analysis with 432 patients, it was
shown that preoperative autologous blood donation was
associated with a reduction in the transfusion rate of PRBC
from 55% to 32% and a 50% reduction in the administration of
FFP and platelet concentrate (PLTC).183 A nested case-control
study (corrected for confounding factors) further revealed that
preoperative autologous blood donation reduced PRBC trans-
fusions by 18.3% in valve surgery.204 This study was,
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tocrit data.204
Based on the current evidence, we suggest that preoperative
autologous blood donation in patients without severe aortic
stenosis, Canadian Cardiovascular Society (CCS) Grade 3–4
angina or ACS o4 weeks and with high Hb levels (4110 g/l)
who are having elective surgery may be considered to reduce
the number of postoperative transfusions.
5.4.5. Acute Normovolaemic Haemodilution
Background. During acute normovolaemic haemodilution
(ANH), the patient donates blood just before the onset of
surgery that is replaced by an equal amount of volume to
maintain normovolaemia. The donated blood is retransfused
after CPB, but this practice comes at the cost of lower
haematocrit values during surgery.
Description of the Evidence. A recent systematic review and
meta-analysis including 29 RCTs investigated the effect of
ANH using a variation of colloid, albumin and crystalloid
volume replacement on allogeneic PRBC transfusion require-
ments in adult and paediatric cardiac surgical procedures.186
The majority of the studies included had no predeﬁned
transfusion protocols. In the 21 studies with allogeneic blood
transfusion as a predeﬁned end point, patients subjected to
ANH received fewer PRBCs (-0.79 units; 95% CI -1.25 to
-0.34; P ¼ 0.001), albeit with a considerable variation in the
effect size between studies.186 Moreover, most of the studies
with a large beneﬁt of ANH on PRBC transfusion were
published before 2001. In the studies reported after 2001, only
half of the studies showed a beneﬁt of ANH on PRBC
transfusion. ANH was associated with a signiﬁcant, but
clinically irrelevant, reduction in postoperative bleeding
(-0.64 ml; 95% CI -0.97 to -0.31; P o0.0001).
In summary, ANH may have a beneﬁcial effect on post-
operative transfusion rates, but this conclusion should be
viewed in light of the older studies included in this meta-
analysis.6. Coagulation and Transfusion
Postoperative diagnosis and guidance of patient haemostasis
and treatment of haemostatic abnormalities by speciﬁc pro-
coagulant interventions or blood transfusion products should
be considered as closing the circle of PBM in cardiac surgery.
6.1. Procoagulant InterventionsRecommendations Classa Levelb RefcAntiﬁbrinolytic therapy (TXA,
aprotinin and EACA) is
recommended to reduce bleeding
and transfusions of blood products
and reoperations for bleeding (TXA
and aprotinin).I A 205–207The prophylactic use of FFP to reduce
bleeding is not recommended.III B 208–210The use of PCC or FFP may be
considered to reverse the action of
VKAs.IIb B 211,212In patients with factor XIII activity
o70% after CPB, the
administration of factor XIII may be
considered to reduce bleeding.IIb B 213,214Prophylactic ﬁbrinogen administration
is not recommended.III B 215In the bleeding patient with a
lowﬁbrinogen level (o1.5 g/l),
ﬁbrinogen substitution may be
considered to reduce postoperative
bleeding and transfusions.IIb B 216–218In patients where bleeding is related to
coagulation factor deﬁciency, PCC
or FFP administration should be
considered to reduce bleeding and
transfusions.IIa B 219,220The prophylactic use of DDAVP to
reduce bleeding is not
recommended.III B 221,222In bleeding patients with platelet
dysfunction on the basis of an
inherited or acquired bleeding
disorder, the use of DDAVP should
be considered to reduce bleeding
and the requirement for transfusions.IIa CThe prophylactic use of rFVIIa to
prevent bleeding is not
recommended.III B 223In patients with refractory, non-
surgical bleeding, off-label use of
rFVIIa may be considered to reduce
bleeding.IIb B 224Bleeding is deﬁned as persistent, non-surgical microvascular blood loss.
aClass of recommendation.
bLevel of evidence.
cReferences.
CPB: cardiopulmonary bypass; DDAVP: desmopressin; EACA: ò-amino-
caproic acid; FFP: fresh-frozen plasma; PCC: prothrombin complex concen-
trate; rFVIIa: recombinant activated factor VII; TXA: tranexamic acid; VKAs:
vitamin K antagonists.
6.1.1. Antiﬁbrinolytics
Background. Antiﬁbrinolytic therapy is widely used to reduce
bleeding, transfusions of blood products and reoperations for
bleeding. Three antiﬁbrinolytics are used to reduce reoperation
for bleeding and blood product transfusion in cardiac surgery:
TXA, aprotinin and EACA. Although aprotinin was withdrawn
from the market in 2007, in some countries, the drug remains
available through a limited access plan.
Tranexamic Acid. The Aspirin and Tranexamic Acid for
Coronary Artery Surgery (ATACAS) RCT compared TXA
with placebo in patients having CABG surgery and
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major haemorrhage (RR 0.36, 95% CI 0.21–0.62; P o0.001)
and in the need for the transfusion of any blood products
(37.9% vs 54.7%; P o0.001).205 This result conﬁrms the
ﬁndings of previous meta-analyses.206,225,226 In a systematic
review and cumulative meta-analysis, it was shown that TXA
reduced the pooled risk ratio for blood transfusion in patients
having cardiac surgery compared with the controls (RR 0.65,
95% CI 0.60–0.70; P o0.001).226 The most signiﬁcant
reported side effect of TXA was convulsive seizure.227,228
The ﬁndings from the ATACAS trial showed that low-dose
(50 mg/kg) versus highdose (100 mg/kg) TXA was not safer in
terms of seizures (0.7 vs 0.6%, respectively), but the higher
dose signiﬁcantly reduced blood loss (P ¼ 0.026) and PRBC
transfusion (P ¼ 0.017).205
Aprotinin. The use of aprotinin in patients having cardiac
surgery has been studied extensively. Several RCTs and meta-
analyses demonstrated its efﬁcacy in reducing the risk of
reoperation for bleeding (RR 0.46, 95% CI 0.34–0.63; P
o0.001) and the need for blood product transfusion (RR 0.68,
95% CI 0.63–0.73; P o0.001).206 It was suggested that
aprotinin was a more effective agent than lysine analogues in
reducing allogeneic blood exposure, but the differences
between the antiﬁbrinolytics were small (RR 0.86, 95% CI
0.76–0.96; P ¼ 0.0083).206 Moreover, most of the studies
were restricted to patients having CABG.207
Data from observational studies229,230 indicated an increased
risk of death associated with aprotinin. In these studies, aprotinin
was preferentially administered to patients with more risk factors
for increased mortality rates at the baseline compared with the
control groups. Several observational studies did not report an
association between aprotinin and safety outcomes.231–233 The
Blood Conservation Using Antiﬁbrinolytics in a Randomized Trial
(BART),234 which was not designed to look at safety, reported
higher mortality rates for patients treated with aprotinin compared
to those treated with TXA or EACA, which led to the regulatory
marketing suspension of aprotinin. Subsequent recognition of the
signiﬁcant limitations of the BART trial, including crossover of
patients in the trial arms,235 and a network meta-analysis showing
no adverse effect of aprotinin compared with placebo and other
agents,232 led to the lifting of the marketing restriction in Canada
and by the European Medicine Agency in 2012 in Europe.236,237
ò-Aminocaproic Acid. In comparison with TXA, limited
data are available to support the use of EACA in cardiac
surgery.206 A meta-analysis of observational studies showed
that the use of EACA reduced the risk for blood product
transfusions (RR 0.70, 95% CI 0.52–0.93; P ¼ 0.015) but did
not decrease the risk of re-exploration for bleeding (RR 0.35,
95% CI 0.11–1.17; P ¼ 0.087).
In summary, safety studies should be designed to deﬁne the
dose–response relationship of the adverse effects observed
following the administration of aprotinin and TXA, given the
positive impact these agents have on bleeding.
6.1.2. Fresh-Frozen Plasma
Background. Fresh frozen plasma is obtained by separating
the plasma, including coagulation factors and other proteinsand soluble constituents of the blood, from particular elements
in donated blood. An increasing number of countries use
pooled plasma. Pooled plasma contains plasma from multiple
donors and is inactivated for viruses with a lower risk of
transfusion-induced lung injury.
Description of the Evidence. The largest body of evidence is
gathered on the prophylactic administration of FFP to patients
without a diagnosed coagulopathy and is summarized in a
Cochrane review208 and 3 other systematic reviews.209,210,238
The RCTs included were limited by small sample sizes and
divergent doses of FFP. There was no difference in blood loss
or allogeneic blood transfusion in patients undergoing cardiac
surgery who received FFP compared with the con-
trols.209,210,238 It was also shown that the therapeutic use of
FFP in patients with established coagulopathy or for reversal
of oral anticoagulation has no effect on 24-h blood loss.209,238
In summary, FFP might be used to reverse the action of oral
anticoagulation or in the case of persistent perioperative
bleeding, but there is no evidence that prophylactic or
therapeutic FFP transfusions reduce blood loss after cardiac
surgery.
6.1.3. Factor XIII
Background. Factor XIII (FXIII) is the terminal enzyme in
the coagulation cascade and is necessary for cross-linking
ﬁbrin monomers to form a stable, strong ﬁbrin clot. Low FXIII
levels have been reported after cardiac surgery and are
associated with increased bleeding.213,239,240 Speciﬁc immu-
nological assays are needed to determine functional FXIII
activity. Detection of FXIII deﬁciency by TEM has been
described,241 but there is currently no clinically available
point-of-care (POC) test.
Description of the Evidence. Three RCTs (n ¼ 527)
evaluated the effect of the administration of FXIII after the
administration of protamine.213,242,243 The results showed no
differences in postoperative bleeding volumes and transfusion
rates with any FXIII dosage regimens. There was no difference
in adverse events, including thromboembolic events and death,
between the intervention and the control groups. However, in
patients with a postoperative FXIII level 70%, the bleeding
volume was higher compared to patients with FXIII levels
470%213; therefore, the latter patients might be the target
population.
In summary, there is no evidence that administration of
FXIII might be beneﬁcial regarding the reduction of post-
operative bleeding volumes and transfusion rates in patients
with normal concentrations of FXIII (470%).
6.1.4. Fibrinogen Concentrates
Background. Fibrinogen is the ﬁrst factor to be depleted
during signiﬁcant bleeding and haemodilution.220,244 Preo-
perative ﬁbrinogen levels o1.5 g/l25 and hypoﬁbrinogenae-
mia after cardiac surgery242,245 have been associated with
increased postoperative bleeding. Fibrinogen supplementation
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static aims in patients who bleed after cardiac surgery.246
Description of the Evidence
Pre- and Postoperative Fibrinogen Substitution. In an
RCT including 48 patients, preoperative ﬁbrinogen substitu-
tion slightly increased intra- and postoperative ﬁbrinogen
concentrations but did not reduce postoperative bleeding in
patients who had CABG (mean blood loss 650 vs 730 ml, P ¼
0.29).247 Postoperative ﬁbrinogen administration was tested in
4 studies, with contrasting results. Two studies248,249 that
included 167 patients undergoing complex cardiac surgery
showed reduced requirements for allogeneic blood products in
the intervention group. In both studies, ﬁbrinogen concentrate
was administered, the goal being a maximal clot ﬁrmness of 22
mm in FIBTEM (ROTEM, Basel, Switzerland). These ﬁndings
are in agreement with a Cochrane systematic review published
in 2013, which showed a reduced relative risk of blood
transfusion after ﬁbrinogen supplementation (RR 0.47, 95%
CI 0.31–0.72).216 However, 2 more recent RCTs in bleeding
patients after complex cardiac surgery could not conﬁrm the
previous ﬁndings.215,250 Indeed, the largest RCT of 152
bleeding patients without hypoﬁbrinogenaemia undergoing
elective aortic surgery, randomly assigned to ﬁbrinogen
concentrate or placebo, found that patients treated with a
ﬁbrinogen concentrate had a signiﬁcantly higher rate of any
allogeneic blood product use compared with placebo (median
units 5.0 vs 3.0, P ¼ 0.026).250 A post hoc analysis from an
RCT showed that substitution with ﬁbrinogen concentrate to
more than 2.87 g/l (or maximal clot ﬁrmness of 14 mm in
FIBTEM) could not further reduce bleeding volume.251 Data
from a Cochrane review including 124 patients from 3 RCTs216
and a propensity score analysis in 380 patients undergoing
cardiac surgery252 suggested no increased risk of thromboem-
bolic events or death after ﬁbrinogen substitution. However,
additional safety data from larger RCTs, which also addressed
different ﬁbrinogen target concentrations, are necessary to
conﬁrm this assumption.
In summary, prophylactic ﬁbrinogen administration is not
recommended for reducing postoperative bleeding and trans-
fusion risks. However, in patients with a low-ﬁbrinogen level
and signs of persistent microvascular bleeding, ﬁbrinogen
substitution may be considered to reduce the requirement for
transfusions.
6.1.5. Prothrombin Complex Concentrate
Background. PCCs are lyophilized, human plasma-derived
vitamin K-dependent coagulation factors. In Europe, only
4 factor concentrates are available, containing coagulation
factors II, VII, IX and X. Although the concentration of factor
IX is standardized, the other factors might vary among the
different available products. Also, PCC might contain various
amounts of AT; proteins C, S and Z and heparin.246,253
Description of the Evidence. In patients with extremely high
INR values (44–5) taking VKAs for the long term who need
urgent or emergent surgery, the use of PCCs might beadvantageous compared with FFP due to the more rapid
reversal of the anticoagulant effect. A Cochrane review,
however, showed no evidence of a difference between PCC
and FFP in terms of postoperative bleeding and transfusion
risks.212 In 40 patients with an INR 42.1, the perioperative
administration of PCC reversed anticoagulation safely; rever-
sal was faster and postoperative bleeding volume was lower
compared with the administration of FFP.211
Three retrospective cohort studies in 402 patients showed
that PCC was associated with fewer re-explorations for
bleeding, less blood loss and fewer transfusions of PRBCs
compared with FFP.219,254,255 The use of PCCs in patients
with bleeding after CPB might be associated with an increased
risk of thromboembolic events and acute kidney injury.255
Recommendations for dosing are not established, and admin-
istration might be tailored to the individual patient based on
laboratory and clinical variables, including POC coagulation
testing.246,253
To summarize, in patients in whom bleeding is related to
coagulation factor deﬁciency, PCC or FFP administration
should be used to reduce bleeding and transfusions. PCC
may be preferred over FFP when rapid normalization of
coagulation factors is needed.
6.1.6. Desmopressin
Background. Desmopressin (DDAVP) is a haemostatic agent
that was developed to prevent and treat bleeding in patients
with mild haemophilia (5–50% of the normal concentration of
clotting factors VIII and IX) and patients with von Will-
ebrand’s deﬁciency, e.g. due to aortic stenosis. DDAVP
stimulates the release of von Willebrand factor from endothe-
lial cells. DDAVP is sometimes administered to treat post-
operative bleeding in patients undergoing cardiac surgery with
impaired platelet function.
Description of the Evidence. The effects of DDAVP on
bleeding in patients having cardiac surgery are summarized in
a Cochrane systematic review of 29 RCTs256 and 2 meta-
analyses.222,257 Summing up the evidence, the prophylactic
use of DDAVP did not reduce blood loss (weighted mean
difference 241 ml, 95% CI -387.55 to -96.01 ml) or the risk of
blood transfusions (OR 0.96, 95% CI 0.87–1.06). Recently
published meta-analyses concluded that DDAVP has a small
effect on the volume of blood loss and allogeneic blood
product transfusions.222,257 Furthermore, the effect of DDAVP
may be more profound in subgroups, e.g. for patients on
platelet inhibitors, patients with reduced platelet function and
patients exposed to prolonged CPB times.222 There was no
increased risk for MI (RR 1.38, 95% CI 0.77–2.50), stroke
(RR 2.40, 95% CI 0.68–8.43) or any thromboembolic com-
plications (RR 1.46, 95% CI 0.64–3.35) after the administra-
tion of DDAVP.256,257 However, the risk of hypotension
during administration of DDAVP that required ﬂuids and/or
vasoactive drugs was signiﬁcantly increased (RR 2.81, 95% CI
1.50–5.27).256
In summary, prophylactic use of DDAVP is not recom-
mended, but its administration might be beneﬁcial in patients
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disorders or platelet dysfunction.258
6.1.7. Recombinant Factor VIIa
Background. Recombinant factor VIIa (rFVIIa) is used in the
treatment and prevention of bleeding in patients with inherited
bleeding disorders. The observed haemostatic properties of this
agent led to its off-label use in life-threatening bleeding, but
nowadays its use is considered to be a last resort in the event
of uncontrollable blood loss.
Description of the Evidence. A 2012 Cochrane review
analysed 29 RCTs with respect to the prophylactic (1361
patients) and therapeutic use (2929 patients) of rFVIIa in
patients with or without haemophilia.224 Prophylactic rFVIIa
use just failed to reach signiﬁcance to reduce transfusion rates
(RR 0.85, 95% CI 0.72–1.01) compared with placebo, but this
result was associated with an increased risk of thromboembolic
adverse events (RR 1.35, 95% CI 0.82–2.25). There was no
beneﬁt of the therapeutic use of rFVIIa compared with the use
of placebo with respect to transfusion rates, but the adminis-
tration of rFVIIa was associated with reduced mortality rates
(RR 0.91, 95% CI 0.78–1.06) at the cost of more major
thromboembolic events (RR 1.14, 95% CI 0.89–1.47).
In summary, prophylactic use of rFVIIa cannot be recom-
mended in cardiac surgery; its therapeutic use should only be
considered in patients with uncontrollable bleeding that cannot
be managed by other procoagulant interventions.
6.2. Transfusion StrategiesRecommendations Classa Levelb RefcImplementation of a PBM protocol for
the bleeding patient is recommended.I CThe use of PRBCs of all ages is
recommended, because the storage
time of the PRBCs does not affect the
outcomes.I A 259,260The use of leucocyte-depleted PRBCs
is recommended to reduce infectious
complications.I B 261Pooled solvent detergent FFP may be
preferred to standard FFP to reduce
the risk of TRALI.IIb B 262Perioperative treatment algorithms for
the bleeding patient based on
viscoelastic POC tests should be
considered to reduce the number of
transfusions.IIa B 263–265It is recommended that one transfuse
PRBCs on the basis of the clinical
condition of the patient rather than on
a ﬁxed haemoglobin threshold.I B 266,267A haematocrit of 21–24% may be
considered during CPB when anIIb B 268adequate DO2 (4273 ml O2/min/m
2)
level is maintained.
Platelet concentrate should be
transfused in bleeding patients with a
platelet count below 50 (109/l) or
patients on antiplatelet therapy with
bleeding complications.IIa CaClass of recommendation.
bLevel of evidence.
cReferences.
CPB: cardiopulmonary bypass; FFP: fresh-frozen plasma; PBM: patient blood
management; POC: point of care; PRBCs: packed red blood cells; TRALI:
transfusion-related acute lung injury.
6.2.1. Quality of Blood Products
Background. Stored PRBCs or FFP reveal comparable
efﬁcacy compared to fresh products but differ in terms of
the risk of the transmission of bacterial or viral infec-
tions,269,270 transfusion-related acute lung injury
(TRALI)271,272 and transfusion-related immune modulation
(TRIM).273–275 To avoid TRALI, FFP and PLTC must be
collected from men, women who have not been pregnant and
women who have tested negative for human leucocyte antigen
antibodies to reduce the risk of TRALI.271 The effects of
TRIM are assumed to be caused by allogeneic mononuclear
cells, white blood cell-derived soluble mediators and human
leucocyte antigen peptides, transfused mainly via PRBCs.273
TRIM has been associated with increased rates of mortality
and morbidity in cardiac surgery and an increased risk of
developing infections.274,275
Description of the Evidence. Leucocyte reduction of PRBC is
the standard practise in Europe and preserves the quality of
PRBC during storage and inﬂuences favourably on morbidity.261
In an RCT, patients having cardiac surgery either received buffy
coat-depleted or leucocyte-depleted erythrocytes.276 Although no
differences in mortality rates could be shown, patients receiving
leucocyte-depleted PRBCs showed a reduced infection rate
compared with the controls (21.6% vs 31.6%; OR 1.64, 95%
CI 1.08–2.49).276 The implementation of new additive solutions
further improved PRBC quality during storage.
In the Red-Cell Storage Duration Study (RECESS), 1098
cardiac surgical patients were randomized to receive exclu-
sively ‘new’ (r10 days) or ‘old’ (Z21 days) leucocyte-
depleted PRBCs.259
There were no differences in multiple-organ dysfunction
and mortality rates between either arm. These results are in
line with the results of a large Swedish registry that compared
the outcomes of 47 071 cardiac surgery patients from 1997 to
2012 who were exclusively transfused with PRBC stored for
o14 days (36.6%), 14–27 days (26.8%), 28–42 days (8.9%)
or of mixed age (27.8%).277 No differences were noted in
terms of 30-day-, 2-year- and 10-year mortality rates or in
relation to 30-day organ dysfunction or serious infection.277 A
current meta-analysis that included the Red-Cell Storage
Duration Study291 and the large Age of BLood Evaluation
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not affect mortality rates, adverse events or nosocomial
infections.278
PLTCs can be produced as single-donor apheresis PLTC or
as pooled (4–5 donors) whole-blood-derived PLTC. Although
the risk for TRALI appears to be comparable, an increased risk
of transmitting infections is associated with whole-blood-
derived PLTC transfusions.279 One retrospective study in
3272 patients who received single-donor PLTC aged 2–5 days
showed no association between PLTC storage age and short-
term outcome, survival or postoperative infections.280 Sol-
vent–detergent treatment and pooling of FFP (SD-FFP) are
performed to inactivate capsulated lipid-enveloped viruses and
dilute human leucocyte antigen antibodies to reduce TRALI.
In a haemovigilance report from Norway (1998–2003), where
SD-FFP is exclusively used, no case of TRALI has been
associated with SD-FFP transfusion, whereas 3 other European
countries have reported incidences of 1.6–8.8 when transfus-
ing FFP.262
In conclusion, we recommend the use of PRBCs of all ages,
because the storage time of the PRBCs does not affect
outcomes. In an attempt to reduce infectious complications,
the use of leucocyte-depleted PRBCs is recommended; in
contrast, the pooled SD-FFP may be preferred over standard
FFP to reduce the risk for TRALI.6.2.2. Algorithm-Guided Therapy of Perioperative Bleeding
Background. The introduction of POC tests—in particular,
TEG and TEM—has led to the development of speciﬁcFigure 3. Haemostatic monitoring throughout the perioperative period and possib
bypass; DAPT: dual antiplatelet therapy; DDAVP: desmopressin; EACA: e-amino
MiECC: minimally invasive extracorporeal circulation circuit; PCC: prothrombin calgorithms to diagnose and, consequently, treat theragnostic
perioperative bleeding in cardiac surgery. The ﬁrst algorithms
were based on TEG, and their effectiveness was tested in a
small series using historical controlled series, ﬁbrinogen
concentration measurements using the Clauss method or a
viscoelastic ﬁbrinogen test.251,281 Figure 3 provides an over-
view of possible monitoring options throughout the periopera-
tive period.Description of the Evidence. A meta-analysis with 5223
patients shows that exposure to any allogeneic blood product
was lower in the POC group (49.6%) than in the conventional
group (60.2%; OR 0.63, 95% CI 0.56–0.71; P o0.0001). This
ﬁnding was conﬁrmed when we considered RCTs only (OR
0.37, 95% CI 0.21–0.68; P ¼ 0.0018). The most relevant
decrease in transfusion rate was related to FFP (OR 0.31, 95%
CI 0.13–0.74), followed by platelet transfusion (OR 0.62, 95%
CI 0.42–0.92) and PRBCs (OR 0.63, CI 0.50–0.78).263 Data
on chest tube drainage in a subpopulation of 400 patients
revealed no differences. Data on the surgical re-exploration
rate favoured the POC group versus the conventional group
(OR 0.56, 95% CI 0.45–0.71; P o0.00001).263 However, a
recently published meta-analysis could not show any beneﬁt of
algorithm-based therapy on surgical reoperation rates.264 There
was a reduction of thromboembolic events in the POC-guided
group versus the conventional group (1.3% vs 2.9%; OR 0.44,
95% CI 0.28–0.70; P ¼ 0.0005). No differences were found
with regard to mortality rates (OR 0.92, 95% CI 0.74–1.16;
P ¼ 0.45).263 The majority of the studies consideredle treatment modalities. ACT: activated clotting time; CPB: cardiopulmonary
caproic acid; EPO: erythropoietin; FFP: fresh-frozen plasma; i.v.: intravenous;
omplex concentrate; PRBC: packed red blood cells.
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reported data inclusive of platelet function tests.263
In 2016, an updated comprehensive Cochrane report that
primarily included cardiac surgery reports assessed the
beneﬁts and harms of TEG- and TEM-guided transfusions
in adults and children with bleeding.282 The use of TEG- and
TEM-guided management was associated with a reduction in
the proportion of patients receiving PRBC transfusions (RR
0.86, 95% CI 0.79–0.94), FFP (RR 0.57, 95% CI 0.33–0.96)
and platelets (RR 0.73, 95% CI 0.60–0.88), whereas there was
no signiﬁcant difference in the rate of surgical reoperation or
bleeding events and massive transfusions.282 In 2015, a
Dutch/British health technology assessment report conﬁrmed
the results of the Cochrane analysis and showed that
viscoelastic testing was cost-effective and more efﬁcient than
standard laboratory testing.283 An additional meta-analysis of
TEG-/TEM-based coagulation management included 9 RCTs
and 8 observational studies comprising 8332 patients.263 The
authors found that TEG-/TEM-based management reduced the
odds for transfusion requirements (OR 0.63, 95% CI 0.56–
0.71) and re-explorations for bleeding (OR 0.56, 95% CI
0.45–0.71) but made no difference in terms of mortality rate,
stroke or chest drain output volume.263 In a subsequent RCT,
7402 patients were randomized to POC haemostatic testing
with an integrated transfusion algorithm or standard of
care.265 POC haemostatic testing reduced the rates of PRBC
transfusions (adjusted RR 0.91, 95% CI 0.85–0.98), platelet
transfusions (RR 0.77, 95% CI 0.68–0.87) and major bleeding
(RR 0.83, 95% CI 0.72–0.94) without affecting complication
rates.265
In summary, the evidence supports the use of perioperative
POC testing in patients having cardiac surgery to reduce
transfusion requirements. Furthermore, it should be noted that
most of the published studies included only viscoelastic
coagulation tests, although a speciﬁc platelet function test
was included in the algorithm in 2 of the more recent
studies.265,284 Cut-off levels for non-acceptable intraoperative
and postoperative platelet function with the different devices
and the subsequent interventions are yet to be determined.
6.2.3. Transfusion Triggers for Packed Red Blood Cells and
Platelet Concentrate
Background. The transfusion threshold is usually deﬁned as
the critical haematocrit/Hb value, red cell volume or platelet
count/function when patients are transfused with PRBCs or
PLTC. However, dynamic strategies also take tissue perfusion/
oxygenation into account.285,286 Data of RCTs in cardiac surgery
are hard to compare, because transfusion thresholds of PRBC
transfusion and the quality of blood products vary among studies.
Description of the Evidence. A recent meta-analysis compared
restrictive (Hb 70–80 g/l) and liberal (Hb 90–100 g/l) transfusion
strategies using data from 6 RCTs with 3352 patients, showing a
30% reduction in the number of deaths in the restrictive regimen
group (OR 0.70, 95% CI 0.49–1.02; P ¼ 0.060).287 The
Brazilian Transfusion Requirements After Cardiac Surgery(TRACS) trial compared a liberal transfusion threshold (haema-
tocrit Z30%) with a restrictive threshold (haematocrit Z24%)
in 502 patients having CABG and/or valve surgery.267 The per
protocol analysis showed that more patients in the liberal group
received red blood cell transfusions (78% vs 48%; P o0.001)
without a difference in the composite end point of 30-day
mortality or severe morbidity.267 A subanalysis of a small
sample of patients older than 60 years (n ¼ 260) showed no
difference in the composite end point between the groups, albeit
with more cardiogenic shock in the restrictive transfusion
threshold group (12.8% vs 5.2%, P ¼ 0.031).288
The UK Transfusion Indication Threshold Reduction
(TITRe2) trial compared a liberal (Hb o90 g/l) with a
restrictive threshold (Hb o75 g/l) for leucocyte-depleted red
blood cells in 2000 patients undergoing CABG and/or valve or
aortic surgery.266 Fewer patients in the restrictive group
received red blood cells (63.7% vs 94.9%; RR 0.58, 95% CI
0.54–0.62; P o0.001), whereas the 90-day mortality rate was
doubled in the restrictive group (4.2% vs 2.6%; OR 1.64, 95%
CI 1.00–2.67; P ¼ 0.045). The TITRe2 study was criticized
regarding transfusion thresholds and confounders, which
might be overcome in the ongoing Transfusion Requirements
in Cardiac Surgery (TRICS III) study.
A small RCT conducted with patients undergoing CABG
with normothermic CPB and not requiring transfusions com-
pared the effect of a haematocrit of 20% (n ¼ 28) with that of
a haematocrit of 25% (n ¼ 26). No differences in oxygen
delivery or consumption, blood lactate levels or clinical
outcome were found.268 In a single-centre investigation in
which surgery was restricted to CABG (n ¼ 3003), a nadir
haematocrit o28% during CPB was associated with an
increase in severe morbidity, whereas lowering the nadir
haematocrit to 24% was possible when a goal-directed
perfusion technique was established, which included main-
tenance of sufﬁcient oxygen delivery.182 These ﬁndings should
highlight the complex interaction of haematocrit, temperature,
oxygen supply and tissue perfusion for tissue oxygenation.
There are no studies available in which a certain platelet
count or value in a platelet function assay served as a threshold
for PLTC transfusion and could be identiﬁed as the key
effector to stop/reduce microvascular bleeding caused by
inadequate platelet count/function.289 However, in recent
American Association of Blood Bank guidelines, a platelet
count of 50 (109/l) was recommended as a therapeutic target
for the bleeding patient undergoing major surgery.290
In summary, recent studies seem to be in favour of liberal
PRBC transfusions. However, from an expert opinion, we
would like to underline that the clinical condition of the patient
and the optimization of the balance between oxygen delivery
and extraction in the tissues are the most important aspects to
be considered rather than a ﬁxed threshold of the level of Hb.
The acceptable haematocrit levels during CPB depend on the
risk proﬁle of the patient and his or her ability to maintain
adequate tissue perfusion and oxygenation. In bleeding
patients with a platelet count below 50 (109/l) or patients on
antiplatelet therapy, PLTC may be transfused.
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Life SupportRecommendations Classa Levelb RefcBivalirudin and argatroban may be
considered as alternatives for heparin
anticoagulation for prolonged ECLS/
ECMO therapy to prevent HIT type 2.IIb CaClass of recommendation.
bLevel of evidence.
cReferences.
ECLS: extracorporeal life support; ECMO: extracorporeal membrane oxyge-
nation; HIT: heparin-induced thrombocytopenia.
The emerging use of extensive extracorporeal life support
(ECLS), e.g. bridge to transplantation, requires novel
approaches towards patient anticoagulation. This chapter
provides an overview of the current evidence on this topic.
Background
ECLS (venoarterial) and extracorporeal membrane oxyge-
nation (ECMO; venovenous) systems are designed for the
temporary support of the failing heart and/or lungs. ECLS
systems are small, closed priming volume systems, including a
centrifugal pump and coated tubing without any option for
removal of air. A cellsaver device replaces cardiotomy suction.
ECLS and ECMO require long-term anticoagulation, which is
associated with an increased risk of thrombosis or bleeding.291
The majority of patients exposed to long-term ECC develop
acquired von Willebrand syndrome.
UFH anticoagulation is the standard in ECLS/ECMO, with
similar dosing challenges to those experienced during cardiac
surgery.292,293 Reagents, clot detection systems and reference
values of different aPTT and ACT assays used during
ECLS/ECMO vary greatly.291–293 Clotting tests do not take
into account disturbances of the coagulation system, which
are especially frequent in patients with multiple-organ failure
requiring ECLS/ECMO support. Strict heparin dosing based
on anti-Xa levels may increase the risk of excessive antic-
oagulation and bleeding.294,295 During the use of AT-inde-
pendent anticoagulants, such as argatroban and bivalirudin,
excessive anticoagulation and bleeding are avoided. How-
ever, in the absence of antidotes, bivalirudin requires
haemoﬁltration to be eliminated from the circulation.296
Moreover, there is no strategy for enhanced extracorporeal
elimination of argatroban, which is predominantly eliminated
via the hepatic system.297
Description of the Evidence
There are signiﬁcant institutional variations in the antic-
oagulation management and monitoring of ECLS/ECMO.298
The dose of heparin anticoagulation depends on the assay,
with broad target ranges for the aPTT of 45–80 s and ACT of140–220 s. Bivalirudin (0.02–0.05 mg/kg/h) and argatroban
(0.1–0.2 mg/kg/h) are usually dosed on the basis of the aPTT
with target ranges of 45–80 s and 50–60 s, respectively.
Particularly in adult patients, data are limited to small,
mostly retrospective, single-centre studies. Clinical outcome
studies are rare and mostly too underpowered to allow one to
draw valid conclusions. In 1 study with 22 patients on ECMO,
low anti-Xa levels were associated with an increase in deep
venous thrombosis.299 This study also showed that the
correlation of ACT or aPTT values with anti-Xa levels was
poor to moderate, respectively.299 In 71 patients, a reduction of
the ACT target value from 180–220 to 140–160 s reduced
bleeding complications and transfusions without increasing
thromboembolic events.300 The role of AT replacement in
ECLS/ECMO remains to be clariﬁed, because the evidence is
limited to paediatric and small studies.298,301 Implementation
of viscoelastic tests for anticoagulation monitoring during
ECLS/ECMO appears to be promising but needs further
validation.298,302 Successful use of bivalirudin303,304 and
argatroban305 during ECLS/ECMO therapy based on aPTT
dosing has been reported in small series in patients with and
without HIT. Bivalirudin anticoagulation, when compared to
heparin, resulted in more stable conditions of the haemostatic
system and reduced bleeding and transfusion rates of
bivalirudin.303,304
In summary, the evidence for an optimal anticoagulation
strategy during ECLS/ECMO is weak, and larger prospective
studies are required.
8. Final Remarks
PBM in cardiac surgery comprises a multidisciplinary and
multifactorial approach and consists of a sequence of separate
strategies and interventions. A key factor in a successful PBM
programme is the close collaboration between surgeons, anaes-
thetists, clinical perfusionists and intensivists. The joint effort of
EACTS and EACTA to write this guideline underlines the
importance of team efforts, and future guidelines should be
extended to enable collaborations with other societies.
Our goal was to provide evidence-based recommendations
with respect to blood-conservation strategies, preoperative
patient optimization, intraoperative interventions and post-
operative monitoring and treatment of bleeding disorders. All
recommendations were based on bleeding-related end points,
which narrowed our search strategy and reference list (Fig. 4).
The lack of consensus on the deﬁnition of bleeding outcomes
and their relevance for patient recovery warrants a consensus
deﬁnition for bleeding complications in cardiac surgery for
future studies. We also aimed to adhere to recommendations
provided by other guidelines in this area.
A closer evaluation of the recommendations included in this
guideline suggests that several fundamental aspects of PBM
programmes are supported by the moderate quality of the
evidence, and large RCTs are warranted to improve the
evidence base of this guideline.
Additionally, it has to be highlighted that a large number of
studies included in this guideline, in particular haemovigilance
Figure 4. Key messages of the Joint Effort Patient Blood Management Guidelines for Adult Cardiac Surgery. ACT: activated clotting time; AT: antithrombin;
CABG: coronary artery bypass grafting; CPB: cardiopulmonary bypass; DDAVP: desmopressin; FFP: fresh-frozen plasma; MUF: modiﬁed ultraﬁltration; PRBC:
packed red blood cells; RAP: retrograde autologous priming; rFVIIa: recombinant factor VIIa.
C. Boer et al. / Journal of Cardiothoracic and Vascular Anesthesia 32 (2018) 88–120112data, are derived from non-European countries. National
regulations for the processing and leucodepletion of PRBCs
differ among countries, and it is therefore unclear whether
non-European data can be translated to the setting of European
patients. We hope that the current guidelines represent a
further step towards the establishment of a European standard
for the quality of blood products, a European haemovigilance
database and European standards for PBM.
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